EP1042674A1 - 148 proteines humaines secretees - Google Patents

148 proteines humaines secretees

Info

Publication number
EP1042674A1
EP1042674A1 EP98956146A EP98956146A EP1042674A1 EP 1042674 A1 EP1042674 A1 EP 1042674A1 EP 98956146 A EP98956146 A EP 98956146A EP 98956146 A EP98956146 A EP 98956146A EP 1042674 A1 EP1042674 A1 EP 1042674A1
Authority
EP
European Patent Office
Prior art keywords
seq
gene
polypeptides
polynucleotides
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98956146A
Other languages
German (de)
English (en)
Other versions
EP1042674A4 (fr
Inventor
Ping Feng
Craig A. Rosen
Steven M. Ruben
Jian Ni
Ying-Fei Wei
Daniel R. Soppet
Paul A. Moore
Hla Kayw
David W. Lafleur
Henrik S. Olsen
Laurie A. Brewer
Yanggu Shi
Reinhard Ebner
Paul Young
John M. Greene
Kimberly A. Florence
Charles Florence
D. Roxanne Duan
Fouad Janat
Gregory A. Endress
Kenneth C. Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1042674A1 publication Critical patent/EP1042674A1/fr
Publication of EP1042674A4 publication Critical patent/EP1042674A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production
  • sorting signals are amino acid motifs located within the protein, to target proteins to particular cellular organelles
  • a sorting signal directs a class of proteins to an organelle called the endoplasmic reticulum (ER)
  • the ER separates the membrane-bounded proteins from all other types of proteins
  • both groups of proteins can be further directed to another organelle called the Golgi apparatus
  • the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane lysosomes, and the other organelles
  • Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein
  • vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis Exocytosis can occur constitutively or after receipt of a triggering signal In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exo
  • the present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.
  • isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
  • an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
  • a "secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
  • a "polynucleotide” refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC.
  • the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
  • a "polypeptide” refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
  • the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis).
  • a representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1 , each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.
  • a “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC.
  • Stringent hybridization conditions refers to an overnight incubation at 42°
  • nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
  • washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
  • blocking reagents include Denhardt's reagent, BLOTTO, heparin. denatured salmon sperm DNA, and commercially available proprietary formulations.
  • the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
  • polynucleotide which hybridizes only to polyA-f sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
  • the polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double- stranded regions.
  • the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • a polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons.
  • Modified bases include, for example, tritylated bases and unusual bases such as inosine.
  • polynucleotide embraces chemically, enzymatically, or metabolically modified forms.
  • the polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
  • the polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side -chains and the amino or carboxyl termini.
  • polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
  • Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, my ⁇ stoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racermzation, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (See, for instance
  • SEQ ID NO X refers to a polynucleotide sequence while “SEQ ID NO Y” refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1
  • a polypeptide having biological activity refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (1 e , the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity lelative to the polypeptide of the present invention )
  • polypeptides of the invention comprise the following ammo acid sequence
  • MRHSQQSCECVRPCMDVYVCVYISIHVYMDAHVYLCRICKTNMR (SEQ ID NO 309), RILRWVNCMACDLYLNKAVSVCAHV ⁇ VMCMCVYISLYMYTWMP MCIYVEYVKQT (SEQ ID NO 310), NPENQLEISFPPRRQKMKLTLDLQVSQS SLVHSLLSSDFFSVSKEGCLWKPILLPSHFL (SEQ ID NO 31 1), LQTQISN YLMFVLHILHRYTWASMYTCffilYTHTYTSIHGRTHSQLC (SEQ ID NO 312), IHMGIHVYMYRDIYTHIHIHTWAHTLTALLRYKSHAIQLTHLNIR (SEQ ID NO:313), and/or MKWIFTVLILTSCFFTAGICEDGICSRIQL RDKIVQSAFRQ (SEQ ID NO:314).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly neutropenia and related conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoeitic, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.. the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. More specifically, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities.
  • T-cell mediated cytotoxicity immune reactions to transplanted organs and tissues, such as host-versus- graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 11 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention.
  • a-b is any integer between 1 to 812 of SEQ ID NO: 1 1
  • b is an integer of 15 to 826, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 1 1, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence:
  • KPCCPSVSNRSSVQMHQLPIQFLGQFEAHCIGFCRSFLETFYTHDPRAMHSFL SSISSPSLPFGFSRMTSQINHLHPSPLC SEQ ID NO:315.
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly neutropenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 161 as residues: Asp- 15 to Tyr-21, Pro-29 to Asn-39.
  • the tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders.
  • the expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia,
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 510 of SEQ ID NO: 12, b is an integer of 15 to 524, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 12, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: SVFKINLKSFKQHEPWWPNRS (SEQ ID NO:316).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, including neutropenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. More specifically, expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may also be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity
  • polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention.
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 477 of SEQ ID NO: 13, b is an integer of 15 to 491, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 13, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in IL-1 and LPS induced neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune disorders, including neutrophenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 163 as residues: Asn-45 to Thr-58.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or prevention of a variety of immune disorders.
  • this gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells.
  • this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus- host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia,
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 389 of SEQ ID NO: 14, b is an integer of 15 to 403, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 14, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence:
  • polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, reproductive, or neural disorders, such as cancers of the breast, lymph system and brain.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 164 as residues: Leu-31 to Phe-38, Glu-47 to Trp-52.
  • the tissue distribution in breast and brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancers in the breast, lymph system, and brain.
  • the protein product of this gene may be useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • neurodegenerative disease states such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysm
  • this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular ⁇
  • Protein as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 15 is related to SEQ ID NO 15 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 799 of SEQ ID NO 15
  • b is an integer of 15 to 813, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 15, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in neutrophils
  • polynucleotides and polypeptides of the mvention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as neutiopenia
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types
  • tissue or cell sample taken from an individual having such a disorder relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 165 as residues Ser-49 to Leu-54
  • the tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of a variety of immune disorders Moreover, the expression of this gene product indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 16 is publicly available and accessible through sequence databases
  • a-b is any integer between 1 to 250 of SEQ ID NO 16 b is an integer of 15 to 264, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 16, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence EKDFMQGSDAGHGGTHIYRALVQWPLAWVFYLSHAKTHWGEELRFSFRRKN LRLREAMRHETCQVTQLVA GKADSNLCLRDSETWFWPPLWAACSSLQATA CRLSSPSKGLGASRECPWLASGRAALVSFL (SEQ ID NO 321), SLRVKGRKPR LLYHSPARGTLWMLPGLCDCL ICRQWLVERSRLPRVGARTRFQSP SDTGWS QLCQLPAV (SEQ ID NO 322), and/or ERSRLPRVGARTRFQSPSDTGWSQLC (SEQ ID NO 323) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and neural diseases, particularly neurodegenerative disorders, such as Alzheimers or Parkinson's Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • tissues or cell types e g immune, hemaopoietic, neural, and cancerous and wounded tissues
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 166 as residues Gln-2 to Gly- 10, Asp-77 to Phe 82
  • tissue distribution in neutrophils combined with the homology to the conserved neurotoxin protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune and neural diseases
  • the protein product of this gene may be useful for the detection/treatment of neurodegenerative disease states, behavioural disordeis, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasm, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception
  • elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function Potentially, this gene product is
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 17 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 506 of SEQ ID NO: 17, b is an integer of 15 to 520, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 17, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: KHAFLMAHQFCVLSLAMQWSSCFQLVALPYLSL (SEQ ID NO:324). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • This gene is expressed primarily in neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as neutropenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders.
  • this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rhe
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 18 is related to SEQ ID NO 18 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 979 of SEQ ID NO 18 b is an integer of 15 to 993, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 18, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence MRPLCVLLPWPCWQWGGLGSASPIRPQAPPGQAAHA
  • This gene is expressed primarily in breast, lymph nodes, spleen, and to a lesser extent, in liver
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to reproductive, immune, or hepatic disorders, particularly cancels of the breast, liver, and lymph system
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g reproductive, breast, immune hematopoietic, hepatic, and cancerous and wounded tissues) or bodily fluids (e g lymph, breast milk bile serum, plasma, urine synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 168 as residues Pro-54 to Gly-67
  • tissue distribution in breast and immune tissues combined with the detected EGR1 and GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancers of the breast and lymph systems Moreover, the GAS and EGR1 activity strongly indicates that the protein product of this gene may play an integral role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders Similarly, such pro ferative tissues rely on finely regulated decisions involving cell differentiation and/or apoptosis Thus this protein may also be involved in regulating apoptosis or tissue differentiation and, thus could be useful in cancer therapy Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences, such as EST sequences are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 19 and may have been publicly available prior to conception of the present invention Preferably, such related polyn
  • polypeptides of the invention comprise the following amino acid sequence ARGLRSPHGAAGVVRGDGGGKKGEDPYSPILFQ SERIPRLIYLPVISSEENS (SEQ ID NO 326) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders, for example, in ameliorating an abberant neutrophil reponse to infectious agents.
  • this gene product may suggest a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells.
  • This gene product may also be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia.
  • neutrophilia neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:20 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 541 of SEQ ID NO:20, b is an integer of 15 to 555, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g reproductive, prostate, and cancerous and wounded tissues) or bodily fluids (e g lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 170 as residues Pro- 14 to Asp-25, Leu-51 to Val-63
  • the tissue distribution in prostate tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of reproductive system disorders such as cancer, particularly prostate cancer
  • the expression within prostate cancer tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders not limited to prostate tissue
  • such tissues rely on decisions involving cell differentiation and/or apoptosis
  • this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 21 is related to SEQ ID NO 21 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 651 of SEQ ID NO 21
  • b is an integer of 15 to 665
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 21
  • b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence
  • KSLSCSFLFLAFWLRRMGQTMCVCVCVCVCVRTWVYLYEPVKF RSPLIYV NLPTS (SEQ ID NO 327), and/or KLGFTMLARLVSNSXTSGDLPSSASQNAGI KGMSYRAWPYSYFLIRKNKQT NKQTKTNPQLGENKHCRNLKVSWSKNYFL (SEQ ID NO 328)
  • Polynucleotides encoding these polypeptides are also encompassed by the invention
  • This gene is expressed primarily in T-cells
  • polynucleotides and polypeptides of the ⁇ n ⁇ ention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders, particularly immunodeficiencies such as lupus and AIDS, or inflammatory disorders Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e
  • tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders Moreover, this gene product may play a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 22 may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 763 of SEQ ID NO 22.
  • b is an integer of 15 to 777. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 22, and where b is greater than or equal to a + 14
  • GAS gamma activating sequence
  • polypeptides of the invention comprise the following amino acid sequence: ERGQGGSSRNVAGSDLVFPAVFVSXLC (SEQ ID NO:329), GSPQGPSVALGSRQCWSRPLRRGGRGAAVEMWRGPTWCFRPSLCLCCVCGV SFGLYVPHGFSLSMCVSAP GSAWLSLVYSICLARGSMSXRXSSRXSLV
  • ASGASVLLVCFWVXADPGVGVSVPRAXVSGLWWCVSPSACLXLAPTKPPP XLSFSLSIFPFSSNPSK (SEQ ID NO:330), and/or TIASLQPTALNHLIWRGW KRKGRLRERKRGXGGAWLGPXRGRQMDSHTTRDQRQXLGEQRHPLLGLXA PRSKPTKQMPQMQPGXPEKKXXLTWNHGLDRWNTQGTARQSLGQK HTWRD (SEQ ID NO:331).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic or neural disorders, particularly obesity, and neurodegenerative or central nervous system disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.adipose, neural, immune, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.. the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in adipose and neural tissues combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of obesity and disorders of the brain and central nervous system.
  • the protein product of this gene may be useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses .
  • this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system
  • the protein product of this gene may also be beneficial in detecting, treating, or preventing neural disorders which occur secondary to aberrant fatty acid metabolism in neural tissues, such as for aberrations in myehn sheath development, or associated autoimmune disorders of neural tissue or the overlying integument Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 23 may have been publicly available p ⁇ oi to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b where a is any integer between 1 to 526 of SEQ ID NO 23
  • b is an mteger of 15 to 540, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 23, and where b is greater than or equal to a + 14
  • polypeptides of the invention compiise the following amino acid sequence ARGPGTEGCEPWLQLQDRRER (SEQ ID NO 332), and/or MSSGTNSFFTLMALNSPTGDSGSRITVSPPRVHPVKSGRGRASDLLLTRFLAPR SALWS (SEQ ID NO 333) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders, such as neutropenia
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level
  • tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of conditions where lymphocytes show abberant response to an infectious agent Similarly, this gene product may play a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent tor immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia.
  • neutrophilia neutrophilia
  • psoriasis hypersensitivities
  • immune reactions to transplanted organs and tissues such as host-versus- graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 24 is publicly available and accessible through sequence databases
  • a-b is any integer between 1 to 470 of SEQ ID NO 24
  • b is an integer of 15 to 484
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 24, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in ovaries, tonsils, and CD34 positive bone marrow stem cells
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but aie not limited to, reproductive, immune developmental, or hematopoietic disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g reproductive, ovarian, immune, tonsil, umbilical, developmental, and cancerous and wounded tissues) or bodily fluids (e g lymph, amniotic fluid, serum, plasma urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, 1 e the
  • tissue distribution in ovarian and tonsil tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful foi diagnosis and treatment of immune and reproductive system disorders Similarly, expression of this gene product in tonsils indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell
  • polypeptides of the invention comprise the following amino acid sequence HEYHLLSSRHILGSVLRLDVC SALWS (SEQ ID NO 334) Polynucleotides encoding these polypeptides are also encompassed by the invention This gene is expressed primarily in JL-1 and LPS induced neutrophils
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as neutropenia
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, reiterate, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • the tissue distribution in immune cells combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders
  • the expression of this gene product in neutrophils indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses)
  • the gene Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersen
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 26 is publicly available and accessible through sequence databases
  • a-b is any integer between 1 to 779 of SEQ ID NO 26
  • b is an integer of 15 to 793
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 26, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in the spinal cord
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, any of a variety of nervous system and neuromuscular disorders, particularly amyotropic lateral sclerosis, musculuar dystrophy, and inherited and non- lnhe ⁇ ted forms of chorea
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g neural, neuromuscular, and canceious and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
  • tissue distribution in spinal cord tissue indicates that this gene could be used for the treatment of spinal cord and related injuries
  • the protein product of this gene could be injected into the spinal cord to promote or control growth following injuring or degeneration
  • cells expressing this gene could be injected or transferred into the spinal cord by other means as a treatment promoting the regulation of growth following spinal cord injury or degeneration
  • polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries ischemia and infarction.
  • this gene product in regions of the brain indicates that it plays a role in normal neural function Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 27 is related to SEQ ID NO 27 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 624 of SEQ ID NO 27 b is an integer of 15 to 638, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 27, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following ammo acid sequence
  • polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in the adrenal gland. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine disorders, particularly disorders of the adrenal gland.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.endocrine, adrenal, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in adrenal tissue, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,hypoparathyroidism) , hypothallamus, and testes.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:28 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b is any integer between 1 to 514 of SEQ ID NO:28
  • b is an integer of 15 to 528
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28
  • b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) oi cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive system disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g placental, reproductive, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 178 as residues His- 15 to Trp-20, Pro-48 to Ala-54
  • the tissue distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of reproductive disorders Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 29 and may have been publicly available prior to conception of the present invention
  • such related polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 905 of SEQ ID NO 29, b is
  • polypeptides of the invention comprise the following amino acid sequence:
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune or reproductive disorders, particularly autoimmune diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.immune, reproductive, testicular, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in testis the homology to an erythrocyte membrane antion-transport protein, in addition to, the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of autoimmune diseases and other immune diseases such as cancer, particularly in, but not limited to, testicular tissue.
  • the translation product of this gene may be important in maintaining normal, cellular homeostasis.
  • the protein as well as antibodies directed to the invention, is beneficial as a therapeutic in order to ameliorate conditions related to aberrant cellular pH regulation (for example, use antibodies to decrease the presence of the protein, or possibly in gene therapy applications in order to replace a defective form, or alternatively, increase the expression of either the endogenous or modified form of the invention)
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 850 of SEQ ID NO 30, b is an integer of 15 to 864, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.30, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in the brain
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, which include, but are not limited to, disorders of the brain and central nervous system, such as neurodegenerative conditions and/or depression.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g neural, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 180 as residues His- 13 to Leu- 18
  • the tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the brain and central nervous system Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasm, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, ma, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding sleep patterns, balance, and preception
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 31 is related to SEQ ID NO 31 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any mteger between 1 to 905 of SEQ ID NO 31
  • b is an integer of 15 to 919, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: PCLQVIGIDFCRLLLMCLVLKRNLTVPFSSYSPLKTITCITSEQIAVVSNFFRQKL GVRAK FFQGACLHTSKVVICLNLPIISIQRADIRMWWLVVNTPYARGVNN
  • This gene is expressed primarily in the spinal cord.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, any of a variety of nervous system and neuromuscular disorders including, but not limited to, amyotropic lateral sclerosis, musculuar dystrophy, and inherited and non-inherited forms of chorea.
  • diseases and conditions which include, but are not limited to, any of a variety of nervous system and neuromuscular disorders including, but not limited to, amyotropic lateral sclerosis, musculuar dystrophy, and inherited and non-inherited forms of chorea.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. neural, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in spinal cord indicates that this gene could be used for the treatment of spinal cord injuries.
  • the protein product of this gene could be injected into the spinal cord to promote or control growth following injuring or degeneration.
  • cells expressing this gene could be injected or transferred into the spinal cord by other means as a treatment promoting the growth or regulation of growth following spinal cord injury or degeneration.
  • This gene may also be useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • neurodegenerative disease states such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms
  • this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:32 is publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 942 of SEQ ID NO:32. b is an integer of 15 to 956, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: VVSVCVLETGQLGPAALCRSV (SEQ ID NO:341). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • This gene is expressed primarily in neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune disorders, which include, nut are not limited to, inflammatory diseases or neutropenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.immune, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treament of the inflammatory conditions.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia,
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:33 Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b is any integer between 1 to 552 of SEQ ID NO:33
  • b is an integer of 15 to 566, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence:
  • GKQSHSTVQLANILHV (SEQ ID NO:350). AGKSHHQVIHWEFEIMLSSYSTDVP (SEQ ID NO:351), and/or HGIICLGFSVYFHRAYTSLCILETAV (SEQ ID NO:352). Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in smooth muscle.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular or vascular disorders, which include, but are not limited to defective organ innervation; deficiencies in neuronal survival; peristaltic abnormalities; digestive disorders; perturbations of the vasculature.
  • diseases and conditions which include, but are not limited to, muscular or vascular disorders, which include, but are not limited to defective organ innervation; deficiencies in neuronal survival; peristaltic abnormalities; digestive disorders; perturbations of the vasculature.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g., cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in smooth muscle tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders that result from failures of normal smooth muscle function
  • this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons Likewise, it may be involved in controlling the digestive process, and such actions as peristalsis Similarly, it may be involved in controlling the vasculature in areas where smooth muscle surrounds the endothehum of blood vessels Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 34 may have been publicly available pnor to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 1550 of SEQ ID NO 34
  • b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 34, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence KRLTINARVHLWTLKSVPL (SEQ ID NO 353), EYVFNMX XYSKSRAISPLSGPYTPRGTTPLPIIPEPGARQRDHPAS LKYAKIIQTKLFAL PYPKETSMKAVA (SEQ ID NO 354), and/or ETVPPRSSQFLKITXGPARSMSLIX XAIQNPEPYLLYLALIPQEALLLYLSSQSQVPGNETTPPV (SEQ ID NO 355) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • This gene is expressed primarily in T-cells
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune system disorders, which include, but are not limited to lupus.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 184 as residues Ser-21 to Thr-34 Thr-38 to Glu-43
  • the tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders
  • Expression of this gene product in T-cells indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell
  • polynucleotide sequences such as EST sequences
  • sequence databases Some of these sequences are related to SEQ ID NO 35 and may have been publicly available prior to conception of the present invention
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1021 of SEQ ID NO:35, b is an integer of 15 to 1035, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence : NEVSFSLSLGFSPREFARWKVNNLAL ERKDFFSLPLPLAPEFIRNI RLLGRRPNLQQVTENLIKKYGTHFLLSATLGGKQHHNPKLIGCQTIGNNV KTRVA (SEQ ID NO:356), VPYFLIRFSVTCCRLGLLPRRRMFRIN SGARGNG KLKKSFLSRAK LFTFQRANSLGEKPRDKEKLTSFQSKRHKI (SEQ ID NO:357), and/or EMSAVLFNQIFCNLLQIGSPSKEANVPDKLWGKRQWQTEEVLPFQSQV VHLPTGKLPGGKAKG (SEQ ID NO:358).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders afflicting endothelial, muscular, and extracellular matrix tissues, which include, but are not limited to fibrosarcomas and bladder cancer.
  • diseases and conditions which include, but are not limited to, disorders afflicting endothelial, muscular, and extracellular matrix tissues, which include, but are not limited to fibrosarcomas and bladder cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.endothelial. urogenital,renal, muscular, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 185 as residues: Pro-49 to Asp-68.
  • tissue distribution in human fibrosarcoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of various cancers, particularly fibrosarcomas and fibroids.
  • the expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders.
  • developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:36 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 606 of SEQ ID NO:36, b is an integer of 15 to 620, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in human tonsil.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, which include, but are not limited to inflammation and infectious diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e g immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, 1 e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in tonsils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of inflammation and infectious diseases Moreover, this gene product may play a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 37 is related to SEQ ID NO 37 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 959 of SEQ ID NO 37
  • b is an integer of 15 to 973
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 37
  • b is greater than or equal to a + 14 FEATURES OF PROTEIN ENCODED BY GENE NO: 28
  • polypeptides of the invention comprise the following am o acid sequence
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g neural, metabolic tissues, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in neural and adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of obesity and disorders of brain and central system Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasm, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception
  • elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 38 is related to SEQ ID NO 38 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 824 of SEQ ID NO 38
  • b is an integer of 15 to 838
  • wheie both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 38, and where b is greater than or equal to a + 14
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 11 Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11
  • polypeptides of the following amino acid sequence are useful as a marker in linkage analysis for chromosome 11
  • This gene comprises polypeptides of the following amino acid sequence
  • FCKHNGSKNVFSTFRTPAVLFTGIVALYIASGLTGFIGLEVVAQLFNC SEQ ID NO 360
  • An additional embodiment is the polynucleotides encoding the polypeptides
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders related to abnormal activation of T cells Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g hematopoietic, developmental, neural, immune, endothehal, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 188 as residues Tyr- 14 to Leu-24. Pro-59 to Gln-66
  • tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders of the immune system related to altered activation of T cells
  • this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of immune disorders
  • the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Theiefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 39 is related to SEQ ID NO 39 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 593 of SEQ ID NO 39
  • b is an integer of 15 to 607, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 39, and where b is greater than or equal to a + 14
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g fetal, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level in healthy tissue or bodily fluid from an individual not having the disordei
  • tissue distribution of this gene primarily in the developing fetus indicates a role in the tieatment and/or detection of developmental disorders and growth defects
  • expression in tumor cell types indicates a role in the detection and/or treatment of tumors
  • expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders
  • embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation
  • this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 40 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 882, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in salivary gland, and to a lesser extent, in other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, digestive and immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. exocrine, digestive, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 190 as residues: Glu-25 to Gly-31, Tyr-62 to Thr-68.
  • tissue distribution in salivary gland tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of digestive and immune system disorders.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed fissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:41 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 945 of SEQ ID NO:41, b is an integer of 15 to 959, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. neurodegenerative and behavioural disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • the tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Furthermore, expression of this gene product within the brain indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 42 may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 861 of SEQ ID NO 42, b is an integer of 15 to 875, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 42, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in the synovium
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases affecting the synovial lining including arthritis and autoimmune disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g endothehal, skeletal, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from
  • chondrodysplasms le spondyloepiphyseal dysplasm congemta, familial osteoarth ⁇ tis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid
  • Protein as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 43 is publicly available and accessible through sequence databases
  • a-b is any integer between 1 to 616 of SEQ ID NO 43
  • b is an integer of 15 to 630
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 43
  • b is greater than or equal to a + 14
  • the gamma activating sequence is a promoter element found upstream of many genes which are involved m the Jak-STAT pathway
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells This gene is expressed primarily in B-cell lymphoma cells
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • tissue or cell types e g immune, cancerous and wounded tissues
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 193 as residues Lys-82 to Pro-90
  • the tissue distribution and biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for for the treatment and or diagnosis of diseases of B-cell lineage including cancer
  • This factor may be useful in the terminal differentiation of malignant cells or may act as a growth factor for B-cell proliferation or differentiation which is supported by the biological assay data Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 44 may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 557 of SEQ ID NO 44.
  • b is an integer of 15 to 571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 44, and where b is greater than or equal to a + 14
  • the gamma activating sequence is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.
  • This gene is expressed primarily in osteoclastoma derived stromal cells, placenta, pancreas and several tumor derived cells and to a lesser extent in brain, melanocytes, dendritic cells, and several other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. tumors of the pancreas, uterus, ovary, bone, or adrenal gland.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. placenta, pancreas, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.. the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or diagnosing tumors of the reproductive organs, pancreas, or bone marrow. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g.
  • pancrease e.g. diabetes mellitus
  • adrenal cortex e.g., ovaries
  • pituitary e.g., hyper-, hypopituitarism
  • thyroid e.g. hyper-, hypothyroidism
  • parathyroid e.g.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 916 of SEQ ID NO:45. b is an integer of 15 to 930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.
  • the interferon- sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. renal and nervous system disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • kidney tissue distribution of this gene in kidney tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of renal disorders including kidney failure and Wilms Tumor in addition to the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO-46 sequences are related to SEQ ID NO-46 and may have been publicly available prior to conception of the present invention.
  • polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 423 of SEQ ID NO 46, b is an integer of 15 to 437, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO -46. and where b is greater than or equal to a + 14
  • An additional embodiment is the polynucleotides encoding these polypeptides
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. metabolic and immune disorders Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types or cell types (e.g.
  • tissue distribution of this gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of endocrine, metabolic, and immune disorders including growth and developmental defects, in addition to the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia.
  • Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:47 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1010 of SEQ ID NO:47, b is an integer of 15 to 1024, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular disorders such as stroke, aneuyrism, cardiac arrest, hemorrhage.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 197 as residues: Cys-14 to Gly-23. Met-45 to Gly-51.
  • the tissue distribution of this gene solely in hemangiopericytoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and or detection of vascular disorders including hemorrhaging, aneuyrism, stroke and cardiac arrest.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:48 is related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention.
  • polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 449 of SEQ ID NO:48. b is an integer of 15 to 463. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.
  • the translation product of this gene shares sequence homology with a serine protease which is thought to be important in regulating the availibility and action of proteins in vivo.
  • This gene is expressed primarily in cerebellum.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. disorders of the central nervous system related to abnormal growth factor regulation, including neurodegenerative conditions such as Alzheimers disease and psychiatric illness such as Schizophrenia.
  • diseases and conditions which include, but are not limited to. disorders of the central nervous system related to abnormal growth factor regulation, including neurodegenerative conditions such as Alzheimers disease and psychiatric illness such as Schizophrenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • CNS cancerous and wounded fissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 198 as residues: Ser-17 to Gln-22.
  • the tissue distribution in neural tissue, combined with the homology to serine proteases indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders of the central nervous system including neurodegenerative diseases and psychiatric disorders.
  • expression of this gene product within cerebral tissue indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia; ALS; or Alzheimer's.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 871 of SEQ ID NO:49, b is an integer of 15 to 885, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, autoimmune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • CD34 depleted buffy coat tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders of the immune system including autoimmune diseases. Furthermore, expression of this gene product in CD34 depleted buffy coat indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).
  • the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:50 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b is any integer between 1 to 833 of SEQ ID NO:50
  • b is an integer of 15 to 847, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of B-cell lineage including lymphomas lymphoblastic leukemias, myelomas and hairy cell leukemia.
  • diseases of B-cell lineage including lymphomas lymphoblastic leukemias, myelomas and hairy cell leukemia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s).
  • tissue or cell types e.g. immune, cancerous and wounded tissues
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in immunce cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for for the treatment and or diagnosis of diseases of B-cell lineage including cancer
  • This factor may be useful in the terminal differentiation of malignant cells or may act as a growth factor for B-cell proliferation or differentiation Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • sequence databases Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 566 of SEQ ID NO.51 , b is an integer of 15 to 580, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 51 , and where b is greater than or equal to a + 14 FEATURES OF PROTEIN ENCODED BY GENE NO: 42
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. autoimmune disorders particularly those of the central nervous system such as multiple sclerosis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • bodily fluids e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:201 as residues: Pro-35 to Ala-40.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating autoimmune disorders such as multiple sclerosis.
  • expression of this gene product in CD34 depleted buffy coat indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).
  • the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 52 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 598
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 52
  • b is greater than or equal to a + 14
  • This gene is expressed primarily in tissues of the brain
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and neurodegenerative disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g CNS, brain, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disordei , relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful as a neuronal protective agent and as a growth factor for cells of the central or peripheral nervous system Furthermore, expression of this gene product within the brain indicates that it may be involved in neuronal survival, synapse formation, conductance, neural differentiation, etc Such involvement may impact many processes, such as learning and cognition Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 53 and may have been publicly available prior to conception of the present invention Preferably, such related polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 9
  • polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9
  • This gene is expressed primarily in embryo and fetal tissues
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • tissues or cell types e g fetal tissues, develpomental, cancerous and wounded tissues
  • bodily fluids e g lymph, amniotic fluid, serum, plasma urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, lelative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in embryonic and fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disoiders Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other prohferative disorders
  • Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division
  • embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation
  • this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above sted tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 54 may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1233 of SEQ ID NO 54, b is an integer of 15 to 1247, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 54, and where b is greater than or equal to a + 14
  • polynucleotides related to this invention aie useful as a marker in linkage analysis for chromosome 2
  • This gene is expressed primarily in infant bram, placenta, seme immune tissues and, to a lesser extent, in other tissues
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and immune disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:204 as residues: Val-32 to Met-39, Leu-44 to Val-49.
  • the tissue distribution in fetal and immune fissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental and immune disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other prohferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division.
  • this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages.
  • this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells.
  • embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation.
  • this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.
  • the protein product of this gene is useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses . autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • neurodegenerative disease states such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurys
  • this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, anfibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO.55 Some of these sequences are related to SEQ ID NO.55 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 834 of SEQ ID NO 55, b is an integer of 15 to 848, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 55, and where b is greater than or equal to a + 14
  • the gamma activating sequence is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells Therefore, activation of the Jak- STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells
  • This gene is expressed primarily in brain tissues, and to a lesser extent, in T- cells
  • polynucleotides and polypeptides of the mvention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neuronal disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, brain, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:205 as residues: Ser-33 to Ser-44
  • the tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal and immune system disorders
  • expression of this gene product in T-cells, as well as the observed biological activity of this gene product indicates that this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses)
  • the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoria
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 56 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 669
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.
  • the gamma activating sequence is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.
  • GAS gamma activating sequence
  • the interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.
  • Contact of cells with supernatant expressing the product of this gene increases the permeability of bovine chondrocytes to calcium.
  • the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the chondrocyte cells.
  • polynucleotides and polypeptides have uses which include, but are not limited to, activating bone cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pregnancy disorders including miscarriage.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, 1 e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in both placenta and breast indicates a role for this protein in the treatment and/or detection of miscarriages in suspect individuals, of birth defects, of breast cancer, and female infertility Furthermore, the biological assay data strongly indicates that the translation product of this gene is actively involved in the initiation of several signal transduction pathways and the activation of several cell types
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 57 is publicly available and accessible through sequence databases
  • a-b is any integer between 1 to 666 of SEQ ID NO 57.
  • b is an integer of 15 to 680. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 57, and where b is greater than or equal to a + 14
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 11 Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11
  • polypeptides of the following amino acid sequence are useful as a marker in linkage analysis for chromosome 11
  • This gene comprises the polypeptides of the following amino acid sequence
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pancreatic related disorders such as diabetes Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • pancreas endocrine, metabolic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, bile, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution of this gene in pancreatic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/detection of endocrine disorders and metabolic disorders associated with the pancreas including diabetes, pancreatitis, and pancreatic cancer.
  • the fissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g.. hyper-, hypopituitarism), thyroid (e.g.
  • hypothallamus e.g. hypothallamus.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:58 is related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention.
  • polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 510 of SEQ ID NO:58. b is an integer of 15 to 524, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in chondrosarcoma tumors.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. including diseases of the skeletal system, particularly with respect to the cartilagenous structures and also cancer of these tissues.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain fissues or cell types (e.g.
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in chondrosarcoma tumors indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/diagnosis of cartilage disorders including arthritis and cancer.
  • Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:59 Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 413 of SEQ ID NO:59, b is an integer of 15 to 427, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.
  • the translation product of this gene shares sequence homology with sorbinwhich is thought to be important in the manufacture of vitamin C. Additionally, sorbin is thought to be important in the process of stimulating water and electrolyte absorption in various cells in the body. Porcine Sorbin has activity in stimulating water and electrolyte absorption across mucosa. It has been pursued as a regulator of electrolyte absorption in the nasal and enteric mucosa. This gene was identified in hypothalamus suggesting that it could play a role in the CNS regulation of water or electrolyte absorption. This gene is expressed primarily in human hypothalamus tissue from a patient suffering from Alzheimer's disease
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurologic disorders (eg Alzheimer's disease)
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g neural, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, counter, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 209 as residues Leu-29 to Leu-37, Gln-65 to Asp-70, Gln-85 to Gly-95
  • tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of Alzheimer's disease
  • the translation product of this gene could be useful for the detection and/or amelioration of disorders involving the CNS regulation of water or electrolyte absorption Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 60 and may have been publicly available prior to conception of the present invention
  • such related polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1249 of S
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • syno ial diseases such as synovial sarcoma Similarl
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • tissues or cell types e g connective tissues cancerous and wounded tissues
  • bodilv fluids e g lymph serum, plasma, u ⁇ ne. synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relativ e to the standard gene expression level, I e . the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in synovium indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of synovial diseases such as arthritis
  • the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e g trauma, tendomtis. chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma.
  • chondrodysplasias le spondyloepiphyseal dysplasia congemta. familial osteoarth ⁇ tis Atelosteogenesis type II. metaphyseal chondrodysplasia type Schmid Protein, as well as. antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO-61 sequences are related to SEQ ID NO-61 and may have been publicly available prior to conception of the present invention.
  • polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 706 of SEQ ID NO:61, b is an integer of 15 to 720, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in immune tissues and fast-growing tissues, such as tumor and early-stage developmental tissues, and, to a lesser extent, in some other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and growth related disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developmental, immune, cancerous and wounded fissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:211 as residues: Ala-28 to Ala-47.
  • tissue distribution in immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of immune and growth related diorders.
  • expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders.
  • embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation.
  • this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:62 Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 575 of SEQ ID NO:62, b is an integer of 15 to 589, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.
  • this gene comprises polypeptides of the following amino acid sequence: DSXLDRRPSGPDVKFLSNKHHFSMVC (SEQ ID NO:364).
  • An additional embodiment is the polynucleotides encoding these polypeptides.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoeitic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain fissues or cell types (e.g. spleen, immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues or cell types e.g. spleen, immune, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:212 as residues: Cys-25 to Trp-30.
  • the fissue distribution of this gene in spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia
  • Expression of this gene product in spleen indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses) Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues Therefore it may be also used as an
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 63 sequences aie related to SEQ ID NO 63 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b.
  • a is any integer between 1 to 672 of SEQ ID NO 63 b is an integer of 15 to 686 where both a and b correspond to the positions of nucleotide r es ⁇ dues shown in SEQ ID NO 63, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in human normal breast, and to a lesser extent, in dendritic cells
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. glandular problems involving cells of epithelial origin including breast cancer Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female endocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. breast, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy fissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:213 as residues: Ser-32 to Asn-44.
  • the tissue distribution in breast tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of both malignant and non-malignant problems of the breast tissues, including cancer.
  • the expression in dendritic tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 64 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b is any integer between 1 to 438 of SEQ ID NO:64, b is an integer of 15 to 452, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.
  • the gamma activating sequence is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, development and immune related diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain fissues or cell types (e.g.
  • bodily fluids e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in embryonic and immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental and immune related diseases.
  • the biological activity data supports the assertion that the translation product of this gene is useful in the treatment and/or diagnosis of diseases related to the immune system.
  • Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.
  • Many polynucleotide sequences, such as EST sequences are publicly available and accessible through sequence databases.
  • polynucleotides comprising a nucleotide sequence desc ⁇ bed by the general formula of a-b, where a is any integer between 1 to 356 of SEQ ID NO 65, b is an integer of 15 to 370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 65, and where b is greater than or equal to a + 14
  • the translation product of this gene shares sequence homology with medicago sativa salt-inducible protein
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal or rheumatoid disorders, particularly, chronic synovitis Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g connective tissues, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 215 as residues Lys-30 to Ser-44, Pro-77 to H ⁇ s-82
  • the tissue distribution in synovium indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of and as a therapeutic agent for chronic synovitis
  • the expression of this gene product in synovium would suggest a role m the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e g arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma.
  • chondrodysplasias le spondyloepiphyseal dysplasm congenita, familial osteoarth ⁇ tis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid
  • Protein as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 66 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 987, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 66, and where b is greater than or equal to a + 14
  • EGR1 Early growth response 1
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the hepatic system
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. liver, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:216 as residues: Lys-57 to Ser-66.
  • the tissue distribution in liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases relating to the liver. Furthermore, the homology indicates that the translational product of this gene may be useful in the detection and treatment of a number of disorders resulting from the improper transport of proteins into the organelle due to defects in peroxisomal membrane proteins, such as Zellweger syndrome. Protein, as well as. antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 67 Some of these sequences are related to SEQ ID NO: 67 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1004 of SEQ ID NO:67, b is an integer of 15 to 1018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.
  • polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental or neurologic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. brain, developmental, and cancerous and wounded tissues) or bodily fluids (e.g.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:217 as residues: Ala- 19 to Lys-34.
  • tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological diseases. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, and/or sexually-linked disorders.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:68 amino acid sequences
  • amino acid sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b is any integer between 1 to 748 of SEQ ID NO:68
  • b is an integer of 15 to 762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.
  • chromosome 16 The gene encoding the disclosed cDNA is thought to reside on chromosome 16 Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, relating to hemopoietic and uterus disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e g lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I
  • T-helper cells and uterine tissues indicate that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders relating to both the immune and female reproductive systems
  • Expression of this gene product in T-cells indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e g by boosting immune responses).
  • the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:69 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 616 of SEQ ID NO:69, b is an integer of 15 to 630, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in human fetal epithelium, and to a lesser extent, in testes.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. developmental or reproductive disorders, in addition to diseases of the integumentary system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • bodily fluids e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in fetal epithelium and testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of epithelium related diseases.
  • polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi. moles. freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e.
  • keratoses Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma
  • injuries and inflammation of the skin i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis
  • atherosclerosis i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis
  • atherosclerosis i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis
  • atherosclerosis i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis
  • atherosclerosis i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis
  • atherosclerosis i.e.
  • lupus erythematosus vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus
  • keloids striae, erythema, petechiae, purpura, and xanthelasma.
  • disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum. herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm).
  • the tissue distribution also indicates that the protein product of this gene is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to by useful in the treatment and/or diagnosis of testicular cancer.
  • the testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:70 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 926 of SEQ ID NO:70, b is an integer of 15 to 940, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.
  • GAS gamma activating sequence
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.
  • This gene is expressed primarily in human adult lymph node and in early stage human lung.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, lymphatitis and pulmonary disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in adult lymph indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases relating to the immune system and respiratory system.
  • expression of this gene product in lymph nodes indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • the biological activity data supports the notion that the translation product of this gene is an activator of various cells of the immune system, and thus could play an important role in the activities of the immune system.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:71 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1089 of SEQ ID NO:71, b is an integer of 15 to 1103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural and immune disorders, such as glioblastosis cerebri.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders relating to the CNS and the immune system.
  • expression of this gene product in T- cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis.
  • immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:72 is publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 885 of SEQ ID NO:72. b is an integer of 15 to 899, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.
  • this gene comprises polypeptides of the following amino acid sequence: CLAEAVSVIQSIPIFNETGRFSFTLPYPVKIKVRFSFFLQIYLIMIFLGLYINFRHLY KQRRRRYGQKKKRSTKKKDLDGFLPV (SEQ ID NO:365).
  • An additional embodiment is the polynucleotides encoding these polypeptides.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary, or neurological and behavioural disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g brain, integumentary and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy
  • disorders may predispose increased susceptibility to viral and bacterial infections of the skin (I e cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm)
  • protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendomtis, chrondomalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasms de spondyloepiphyseal dys
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 535 of SEQ ID NO:73, b is an integer of 15 to 549, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence:
  • LCSTPVPTLFCPRIVLEVLVVLRSISEQCRRVSSQVTVASELRHRQWVERTLRSR QRQNYLR SEQ ID NO:366
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal disorders, and diseases of the haemopoietic and immune system, particularly cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.skeletal,hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, 1 e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 223 as residues Ser-59 to Glu-67
  • the tissue distribution in osteoclastoma tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatement and diagnosis of disorders of the bones, immune and haemopoietic systems and cancer
  • the protein may play a role as a therapeutic in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disordeis afflicting connective tissues (e g arthritis, trauma, tendomtis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders
  • connective tissues e g arthritis, trauma, tendomtis, chrondomalacia and inflammation
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 74 is publicly available and accessible through sequence databases
  • polynucleotides aie specifically excluded from the scope of the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 576 of SEQ ID NO 74, b is an integer of 15 to 590, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 74, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence:
  • ARGETAYDGAAVEFQEPLSSCLFSSLNPHHWPTLGVGRPVMLTLEDKD SEQ ID NO:367
  • polypeptides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in testes. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, male reproductive and endocrine disorders, cancer, particularly testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. reproductive, testes, endcrine, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:224 as residues: Lys-53 to Leu-60, Pro-94 to Gln-99, Ser- 176 to Gly- 184, Ser- 199 to Val-207.
  • the tissue distribution in testes, combined with the detected EGRl biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of male reproductive and endocrine disorders, including aberrant testicular function (e.g. endocrine function, sperm maturation). Moreover, in light of the EGRl activity, it may also be useful in the diagnosis and treatment of a variety of prohferative disorders, especially testicular cancer. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:75 Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention.
  • related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1042 of SEQ ID NO:75, b is an integer of 15 to 1056, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: QSWTAPAARLPMALPQMCDGSHLASTLRYC (SEQ ID NO:372), QSAAQWFWWPGRSASLGGAKGMQPPSLASWPXPRSIRCL RAPAPC SXPSASSAAVQVACCCSLACCGPSRPASQGHLRWDPYHLSRDLYYLTVESSEK ESCRTPKVVDI PTYEEAVSFPVAEGPPTPPAYPTEEALEPSGSRDALLSTQPA WPPPSYESISLALDAVSAETTPSATRSC SGLVQTARGGS (SEQ ID NO:373), GSTGLWRGDRGPIEGGPGMLAL TDHSRVSFPVAEGPPTPPAYPTEEAL EPSGSRDALLSSVXGASWPGWAVASPSLHQAKQSVPATRTTVPLTVM Q (SEQ ID NO:374), QWFWWPGRSASLGGAKGMQPPSLASWP (SEQ ID NO:375), SSAA VQVACCC
  • VSFPVAEGPPTPPAYP TEEALEPSGSRDALLS SEQ ID N0.377
  • RVSFPVAEGPPTPPAYPTEE ALEPSG SEQ ID NO:378,
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine disorders, such as dwarfism.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.endocrine, immune, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in pituitary indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the pituitary gland and endocrine system.
  • the protein product of this gene would also be useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g.
  • hypothallamus e.g. hypothallamus, and testes.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:76 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 916 of SEQ ID NO:76, b is an integer of 15 to 930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: SNEILLSFPQNYYIQWLNGSLIHGLWNLASLFSNLCLFVLMPFAFFFLESEGFA GLKKGIRARJLETLVM LLLLALLILGIVWVASALIDNDAAS (SEQ ID NO:379).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.
  • This gene is expressed primarily in the developing brain, liver and heart,and to a lesser extent, in cancerous tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental,neural, hepatic, or cardiopulmonary and haemopietic disorders, in addition to cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • bodily fluids e.g. lymph, amniotic fluid, bile, serum, pulmponary surfactant or sputum, plasma, urine, synovial fluid and spinal fluid
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:226 as residues: Glu-67 to Asn-74. Glu-88 to Asn-93, Lys-95 to Ser-105, Arg-152 to Ala- 164. Ala-204 to Arg-210, Phe-254 to Thr-262, Pro-295 to His-31 1.
  • tissue distribution in developing brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of haemopoietic and developmental diseases and cancers. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • neurodegenerative disease states such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease,
  • this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis. or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the relatively specific expression of this gene product during embryogenesis indicates that it may be a key player in the proliferation, maintenance, and/or differentiation of various cell types during development. It may also act as a morphogen to control cell and tissue type specification.
  • this gene product may have applications in the adult for tissue regeneration and the treatment of cancers, which include, but are not limited to the following tissues or cells: pulmonary, immune, neural, hematopoietic, or hepatic tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:77 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4449 of SEQ ID NO:77, b is an integer of 15 to 4463, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: PTRPVLLLAINGVTECFTFAAMSKEEVDRYNFV (SEQ ID NO:380), and/or NDKKLLFLKGFWSSLKNETPPPHFRLRMVTGVSCSGTLWCLISGV AVTPLQSPQWG SYTECVPPTELPIAGPGASGVQASLKSRHFVSASGHT (SEQ ID NO:381). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive organs, immune, and pulmonary systems, in addition to endothehal and epithelial tissues Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune, respiratory and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g pulmonary, immune, reproductive, testes, epididymus.
  • tissues or cell types e g pulmonary, immune, reproductive, testes, epididymus.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 227 as residues Arg-45 to Thr-52, Tyr-60 to Gly-66, Ala-87 to Trp-92, Leu- 105 to Ser- 1 15
  • the tissue distribution and homology to putative transmembrane protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the reproductive, pulmonary and immune system
  • the protein product of this gene may be useful in the diagnosis, treatment, and/or prevention of a variety of male repioductive disorders, which include but are not limited to, aberrant testicular function, male sterility, impotence, or related endocrine disorders Protein may also serve a role as a contraceptive Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 78 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 791, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: SENRIYRNGLEKMRREVTIGRSSSICLDQQVKAGNAVHHQWLKYVCWMVVVV GGSGVGDGG NLGM (SEQ ID NO:382). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as inflammatory or immunodeficiency conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells.
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues or cell types e.g.immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:228 as residues: Ser-62 to Thr-73, Phe-80 to Gln-88.
  • tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and diagnosis of immune system disorders. More specifically, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:79 is publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1278 of SEQ ID NO:79. b is an integer of 15 to 1292, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in monocytes.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune or hematopoietic disorders, which include, but are not limited to, leukemias, lymphomas, AIDS, arthritis and asthma.
  • diseases and conditions which include, but are not limited to. immune or hematopoietic disorders, which include, but are not limited to, leukemias, lymphomas, AIDS, arthritis and asthma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.immune, hematopoietic, and cancerous and wounded fissues) or bodily fluids
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, 1 e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • the tissue distribution in monocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including leukemias, lymphomas, immunodeficiencies (e g AIDS), immuno-supressive conditions (transplantation) and hematopoietic disorders
  • this gene product may be applicable in conditions of general microbial infection, inflammation or cancer
  • this gene may also be useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopema, leukopenm, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution radiotherapy or chemotherapy of neoplasm
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc
  • this gene product may have
  • EGRl epidermal growth response gene 1
  • polypeptides of the invention comprise the following amino acid sequence: NWSGRRLRMWPSAALSPAVSSPALALTSPPKPLKGENWLRWKLLGSRAVGLF AF IALGTQSPLLHRACLPVRQSWGCSEHKAYPILRLQPDLETQVGPGHGVN WDLRTQIRTIGELGGDGGCSE MRPLF (SEQ ID NO:383), and/or NLFSTPCKRQ KLIKLEWTEAPNVALRCSLSCSLIPGLSPDLSSEAPEGRSVAKMEIARQQSCWL VCI YCFRNPESTLAPGLPACEAELGLLRAQGLPHPASPARLGNTGGAWPR SKLGSQNTN (SEQ ID NO:384), SSPALALTSPPKPLKGEVWLRWKLLG (SEQ ID NO:385).
  • EHKAYPILRLQPDLETQVGPGHGVNWDL SEQ ID NO:386
  • ALRCSLSCSLIPGLSPDLSSEAPEGRSV SEQ ID NO:387
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 1 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1 1.
  • This gene is expressed primarily in placenta.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, pre-natal disorders and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, placental, and cancerous and wounded tissues) or bodily fluids (e.g.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:230 as residues: Gly-22 to Gly-29, Gln-37 to Ala-44.
  • tissue distribution in placental tissue combined with the detected EGRl biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental anomalies, fetal deficiencies and pre-natal disorders. In addition it may be useful in the detection and treatment of ovarian and endometrial cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed fissues.
  • polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 694 of SEQ ID NO: 81 , b is an integer of 15 to 708. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: LAPECCCGSVTYPRALVPRPCCPEPRAPLQLTLGLFSANPVNASPWGRCRSRR GRGNLPLGHPVSTAFSSGDS (SEQ ID NO:388), and/or NTLHSKLVPSVYHSTE KSCLV CFGMCPSIYKKMKSVLLIGTRMLLWLSHISQGPRPEAVLPRAPSP SAAHPWLVFRKPGKRKPLGQMQKQK REGKPASGSPC (SEQ ID NO:389), YPR ALVPRPCCPEPRAPLQLTLGLF (SEQ ID NO:390), and/or VLLIGTRMLL WLSHISQGPRPEAVLPR (SEQ ID NO: 391 ).
  • polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.
  • This gene is expressed primarily in infant brain, and to a lesser extent, in placenta.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e g reproductive, developmental, neural, and cancerous and wounded tissues
  • bodily fluids e g lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 231 as residues Thr-45 to Arg-50
  • the tissue distribution in fetal brain and placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of various developmental and neurological disorders and diseases
  • the protein product of this gene is useful for the detection/treatment of neurodegenerative disease states behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease.
  • Tourette Syndrome meningitis, encephalitis demyehnating diseases, peripheral neuropathies neoplasm, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception
  • elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system Expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role
  • polypeptides of the invention comprise the following amino acid sequence WIIVMFGKVLKIKDFMSTYSHTYTHTHMHAHTHTHTLTLSLLQNVLTLVAISDS DK ALLIF (SEQ ID NO 392), MTLLIAEKTWRRPWPCQWGYLGAEGDRHLEG RSLSLRHLQGAETPVLNPDLQLPSHIGKQAWSH ALGSL (SEQ ID NO 393), MSTYSHTYTHTHMHAHTHTHTLTLSLL (SEQ ID NO 394), and/or GAEGDRHLE GRSLSLRHLQGAET (SEQ ID NO 395) Polynucleotides encoding these polypeptides are also encompassed by the invention This gene is expressed primarily in the spleen of patients with lymphocytic leukemia
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, lymphocytic leukemia and other cancers, as well as immune disorders such as AIDS, arthritis and asthma Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level
  • tissue distribution in spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of lymphocytic leukemia and other cancers, as well as other immune disorders and conditions including, AIDS, arthritis, asthma and microbial infection
  • the protein product of this gene may be useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenm, thrombocytopema or leukemia since stromal cells are important in the production of cells of hematopoietic lineages
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasm
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 83 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 616, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 83, and where b is greater than or equal to a + 14
  • GAS gamma activating sequence
  • EGRl eye growth response gene 1
  • polypeptides of the invention comprise the following amino acid sequence: VVEPGLKASLGA
  • This gene is expressed primarily in cells of the immune and haemopoietic systems, and to a lesser extent, in several other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and haemopoietic disorders, such as multiple myeloma, immunodeficiencies, and inflammatory conditions.
  • diseases and conditions which include, but are not limited to, immune and haemopoietic disorders, such as multiple myeloma, immunodeficiencies, and inflammatory conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain fissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g. lymph. serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or cell types e.g., cancerous and wounded tissues
  • bodily fluids e.g. lymph. serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID
  • tissue distribution in immune tissues and cells combined with the detected GAS and EGRl biological acitivity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, haemopoietic, and integumentary systems.
  • polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia. leukopenia.
  • stromal cells are important in the production of cells of hematopoietic lineages
  • the uses mclude bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasm
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 84 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 928, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 84, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence MGFDIHGVLGEAVAEPREKKQE RAKWAPHDYDDPSLS
  • polynucleotides encoding these polypeptides are also encompassed by the invention
  • the gene encoding the disclosed cDNA is believed to reside on the X chromosome Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome
  • This gene is expressed primarily in fetal liver and spleen, and to a lesser extent, m prostate cancer and placenta
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, reproductive, immune, and haemopoietic disorders Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune system and developing systems, expression of this gene at significantly higher or lower levels may be detected in certain fissues or cell types (e.g.developmental, hepatic, reproductive, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • fissues or cell types e.g.developmental, hepatic, reproductive, immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, amniotic fluid, serum, bile, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a
  • tissue distribution in developing and immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the haemopoietic and developing immune systems.
  • polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution. radiotherapy or chemotherapy of neoplasia.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • the expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders.
  • developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.
  • the protein may also show utility in the treatment or diagnosis of various hepatic or reproductive disorders, which include, but are not limited to hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells, and prostate cancer, and/or congenital defects such as X-linked conditions.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 85 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 709 of SEQ ID NO:85, b is an integer of 15 to 723, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic, immune, developmental, or renal disorders, such as congenital defects, mutliple myeloma, or Wilm's tumor.
  • diseases and conditions which include, but are not limited to, haemopoietic, immune, developmental, or renal disorders, such as congenital defects, mutliple myeloma, or Wilm's tumor.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.developmental, immune, hematopoietic, renal, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the haemopoietic and developing systems and cancer.
  • polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 86 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 86, and where b is greater than or equal to a + 14
  • GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells
  • activation of the Jak-STAT pathway reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory diseases Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hematopoietic.
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • the tissue distribution in T-cells. combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune and inflammatory diseases
  • the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors to identify agents that modulate their interactions and as nutritional supplements It may also have a very wide range of biological acitivities Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines, immunostimulating/immunosuppressant activities (e g for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy), regulation of hematopoiesis (e g for treating anaemia or as adjunct to chemotherapy), stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e g for treating wounds, stimulation of follicle stimulating hormone (for control of fertility), chemotactic and chemokinetic activities
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 87 and may have been publicly available prior to conception of the present invention
  • such related polynucleotides are specifically excluded from the scope of the present invention
  • a-b where a is any integer between 1 to 625 of SEQ ID NO 87, b is an integer of 15 to 639, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 87, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence QSVPSPPLAPPLPPSLPSFLFTETRSHYVARLVSNSWAQM ILLPWPLKVLGLDVSHCAWPKSVFLQAMEEIADFCLFSVKYQVSSMTCF DRT SYMKNTYL (SEQ ID NO 402), and/or LFTETRSHYVARLVSNSWAQMILLPWP (SEQ ID NO 403) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • This gene is expressed primarily in bone marrow
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • anemias leukemias
  • immune deficiencies and other hematopoietic-related disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of hematopoietic and immune disorders, which include, but are not limited to the following leukemias, lymphomas, auto-immunities, immunodeficiencies (e g AIDS), immuno-supressive conditions (transplantation) and other hematopoeitic disorders, such as multiple myeloma
  • this gene product may be applicable in conditions of general microbial infection, inflammation or cancer Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 88 sequences are related to SEQ ID NO 88 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 694 of SEQ ID NO 88.
  • b is an integer of 15 to 708, where both a and b correspond to the positions of nucleotide residues shown m SEQ ID NO 88, and where b is greater than or equal to ⁇ + 14
  • polypeptides of the invention comprise the following amino acid sequence SQIKSEKKHIGKAYTCTQTQSTGMQSTLTIVAKKKSRNHTESYTRKKQENQIV LIPWHQKKHPEGTHTCSHSLRRDTNTAADTQRKIRAHRYTYRRDKYSDTLVTH DHYKGDKHPSNTHTQPR XEFLQPGGSTNSRAAAPRXSSSFCPFS EGYS SWGYH (SEQ ID NO 404),GMQSTLTIVAKKKSRNHTESYTRKKQ (SEQ ID NO 405), KKHPEGTHTCSHSLRRDTNTAADT (SEQ ID NO 406), and/or RRDKY SDTLVTHDHYKGDKHPSNT (SEQ ID NO 407) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • This gene is expressed primarily in neutrophils
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as leukemias, lymphomas, AIDS, arthritis and asthma Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:238 as residues: Asp-38 to Leu-43.
  • the tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including leukemias, lymphomas, AIDS, arthritis and asthma, as well as other conditions which potentially implicate the immune system, such as atherosclerosis, cancer and infection.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia. neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity: immune reactions to transplanted organs and tissues, such as host-versus- graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • immunodeficiency diseases such as granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia. neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity: immune reactions to transplanted organ
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:89 amino acid sequence sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 935 of SEQ ID NO 89, b is an integer of 15 to 949, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 89, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence KHLPLKAPIDLDNKNSCMFCSRDIFCRFH HSTAWLFL GRITDRILGLHHYLIRYQFEIENLCLMKIVIPVVSMKTNCQFDFLGQLKQNLYH (SEQ ID NO 408), APIDLDNKNSCMFCSRDIFCR (SEQ ID NO 410), and/or ffiNLCLMKTVIPVVSMKTNCQFDFLGQL (SEQ ID NO 409) Polynucleotides encoding these polypeptides are also encompassed by the invention This gene is expressed primarily in prostate carcinoma cell line stimulated with
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e g lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in the prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for the disgnosis and intervention of prostate cancer and prostate ailments, or related prohferative conditions in either said tissue or other tissues Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues 1 1 !
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:90 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1157 of SEQ ID NO:90, b is an integer of 15 to 1171, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.
  • the translation product of this gene shares strong sequence homology with human protocadherin 42 (GenBank accession no. gil387675), PCDH7 (BH-Pcdh)a, and its associated isoforms PCDH7 (BH-Pcdh)b, and PCDH7 (BH-Pcdh)c which are thought to be important in tissue and cell-cell adhesion, repair and development (See Genbank Accession Nos.gnllPIDIdl026122 (AB006755), gnllPIDIdl026123 (AB006756), and gnllPIDIdl026124 (AB006757)).
  • the polynucleotides encoding this gene have been gened by another group subsequent to our filing (See Yoshida K, et al. Genomics 1998 May 1 ;49(3):458-61, which is hereby incorporated by reference).
  • the cytoplasmic domain of cadherin interacts with the cytoskeleton through catenins and other cytoskeleton associated proteins.
  • the cytoplasmic domain is not present in all cadherins, but in those which possess it, it is essential for the cadherins adhesive function.
  • the cadherins which do not possess a cytoplasmic domain appear to function via a different method from those with a cytoplasmic domain. This protein sequence is involved in cell-cell adhesion.
  • BH-Pcdh has an extracellular domain consisting of seven repeats of the cadherin motif (EC 1 to 7).
  • EC2 of BH-Pcdh is unique in having a 55-amino-acid insertion in the middle of the motif.
  • polypeptides of the invention comprise the following amino acid sequence: GTSVNESVSNATAIDSQIARSLHIPLTQDIAGDPSYEISKQRLSIVIGVVAGI (SEQ ID NO:41 1), PKIKMAMKPAKKITKTFLHPNSMTNLKSLKRTRKTKNLSSLSTA ALSLWRLLSQMDRGMIVSMRSCQTAQ AWGDTGPLMVGPAVLTWQG ⁇ TNL VPHCLLFSFIPSHQLQEKNTRPYKIYHQPTHLWEQETTFQLDQITAL STAVKP ITSTANRCVYIHTLLCLAEFHSNMMLHYAPYCDDLSTPKPAGACPWPWGVSQS LLVPLVVHFIF ESFSFSYTEK (SEQ ID NO:412), CSIMHHTVMTFLLRNLLEPA LGRGVSANHCLFHLLYILFL SLFLSHIQKNSMKIK (SEQ ID NO:413), TAIDS QIARSLHIPLTQDIAGDPSYEISK (SEQ ID NO:
  • EDFF (SEQ ID NO:415), GPGSPDLARHYKSSSPLPTVQ (SEQ ID NO:416), and/or LPPANTFVGAGDNISIGSDHCSEYS (SEQ ID NO:417).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4. This gene is expressed primarily in ovarian tumors, and to a lesser extent in, striatum and HL-60 cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and reproductive dysfunction, in addition to cardiovascular and neural disorders, such as atherosclerosis, and neurodegenerative disorders, such as Alzheimer's and Parkinson's, or other disorders resulting from aberrant cell-adhesion.
  • diseases and conditions which include, but are not limited to, cancer and reproductive dysfunction, in addition to cardiovascular and neural disorders, such as atherosclerosis, and neurodegenerative disorders, such as Alzheimer's and Parkinson's, or other disorders resulting from aberrant cell-adhesion.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.reproductive, neural, cardiovascular, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:240 as residues: Tyr-15 to Leu-59, Ala-68 to Asp-85, Pro-87 to Asn-96, His-120 to Lys- 129, Ser- 153 to Gin- 170.
  • tissue distribution in ovarian and muscle tissue combined with the strong homology to various cadherins indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, study and treatment of various neoplastic disorders such as squamous cell carcinomas and related tumors, and nervous system and reproductive disorders.
  • neoplastic disorders such as squamous cell carcinomas and related tumors, and nervous system and reproductive disorders.
  • chemotaxis by the immune and hematopoietic cells indicates that this gene product may play a direct, or in-direct role in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).
  • the gene Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS,
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also play an in-direct role in the regulation of a very wide range of biological acitivities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g.
  • hematopoiesis e.g. for treating anaemia or as adjunct to chemotherapy
  • stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 91 sequences are related to SEQ ID NO 91 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1137 of SEQ ID NO 91, b is an integer of 15 to 1151 , where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 91, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer, or other immune or reproductive disorders and diseases Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, reproductive, breast, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, breast milk, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 241 as residues Cys-34 to Gly-48
  • the secreted protein may have a very wide range of biological acitivities Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines, immunostimulating/immunosuppressant activities (e g for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy), regulation of hematopoiesis (e g for treating anaemia or as adjunct to chemotherapy), stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e g for treating wounds, stimulation of follicle stimulating hormone (for control of fertility), chemotactic and chemokinetic activities (e g for treating infections, tumors), hemostatic acitivities Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines, immunostimulating/immunosuppressant activities (e g for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy), regulation of hematopoiesis (
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 92 sequences are related to SEQ ID NO 92 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 700 of SEQ ID NO 92, b is an integer of 15 to 714, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 92, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence QPDIPVLPVGFSQNCSFKVSGCWKGGLIAEKVGTLGTPKGRR AWPETEF FRFLEPGLP (SEQ ID NO 421), and/or RGFRMAQPLVNTFQVAVPVEDL
  • This gene is expressed primarily in activated T-cells. hepatocellular tumor, pancreas islet cell tumors, and hemangiopericytoma
  • polynucleotides and polypeptides of the mvention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hepatic, and endocrine disorders, such as cancers, particularly of T-cells, hepatocellular tumors and pancreas islet cell tumors Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, hepatic, endocrine, and cancerous and wounded tissues) or bodily fluids (e g lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from
  • tissue distribution in T-cells, hepatocellular tumors, and pancreatic islet cell tumors indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of immune, hepatic, and endocrine disorders, and other cancer types
  • Expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders in vaiious tissues, aside from those disclosed above
  • developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences, such as EST sequences are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 93 and may have
  • a is any mteger between 1 to 796 of SEQ ID NO 93
  • b is an integer of 15 to 810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 93, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence
  • Polynucleotides encoding these polypeptides are also encompassed by the invention This gene is expressed primarily in hepatocellular tumors
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatic disorders, such as liver diseases and hepatocellular tumor, including prohferative disorders in other tissues and cell types.
  • diseases and conditions which include, but are not limited to, hepatic disorders, such as liver diseases and hepatocellular tumor, including prohferative disorders in other tissues and cell types.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in hepatocellular tumor tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of hepatocellular tumor or other liver disorders. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • liver disorders and cancers e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:94 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1 162 of SEQ ID NO:94, b is an integer of 15 to 1176, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.
  • GAS gamma activating sequence
  • polypeptides of the invention comprise the following amino acid sequence: NCDHDFIQPLHTPMSAL FQSEFS (SEQ ID NO:427), SILNM GLFTEQRPWPAAARCARQSTVAGAIRRARGTVTMWQVAGAAW ASPDRRAKV HPCRHAAPCLPSPCRRGLQMSGPLQATRGRVTLRSHQVGCKRATGSIENSL (SEQ ID NO:428), QKSKGSPLQTCCSLPTLPMQERPADEWSTPGDQGKSYIK KPPGGLQKGHRLHRKLTLKQGRHRGVE GLNEIMVTVLKEEFPVSKPGLNV LPTFHRHHECYQHGMNLTARISVVS (SEQ ID NO:429), ARQSTVAGAIRR ARGTVTMWQVAGA (SEQ ID NO:430), PCRRGLQMSGPLQATRGRVTLRSHQ (SEQ ID NO:431), LPMQERPADEWSTPGDQGKSYIKKPP (SEQ ID NO:427),
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal, developmental, reproductive, immune, or hematopoietic disorders, particularly kidney disease, lymphoma, congenital defects, multiple myeloma, SCID, male sterility, and cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.immune, hematopoeitic, reproductive, renal, developmental, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID
  • tissue distribution in fetal kidney and T-cells, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatement of kidney diseases or immune disorders, especially cancers.
  • kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome.
  • kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's
  • Protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders.
  • developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.
  • this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.
  • Protein, as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:95 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1014 of SEQ ID NO:95, b is an integer of 15 to 1028, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.
  • GAS gamma activating sequence
  • This gene is expressed primarily in breast, human embryo, and chronic spleen lymphocytic leukemia.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, developmental, hematopoietic or immune disorders, such as breast cancer, congenital birth defects, or leukemia Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the breast or hematopoietic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.reproductive.
  • tissue oi cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO.245 as residues: H ⁇ s-2 to Asn-8, Gln-35 to Phe-44
  • tissue distribution in breast and lymphocytic leukemia cells combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or intervention of breast cancer, leukemia or other hematopoietic related disorders Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:96 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 733 of SEQ ID NO:96, b is an integer of 15 to 747, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly specific brain tumors such as medulla blastoma, as well as other diseases and conditions of the brain, such as schizophrenia, Alzheimer's disease, Tourette's syndrome, Parkinson's disease. Huntington's disease, mania, dementia, paranoia, depressive and addictive predispositions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.neural, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of specific brain tumors such as medulla blastoma.
  • it may also be useful for the diagnosis and treatment of developmental, degenerative and behavioral conditions of the brain and nervous system, such as schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, mania, dementia, paranoia, addictive behavior, obsessive-compulsive and sleep disorders.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:97 Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention.
  • related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 614 of SEQ ID NO:97, b is an integer of 15 to 628, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 97, and where b is greater than or equal to a + 14.
  • GAS gamma activating sequence
  • polypeptides of the invention comprise the following amino acid sequence: INVLYCSRDSLMGRT1MESSDYIKKGANVSPVLGVRQQ AV (SEQ ID NO:434). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the endocrine and immune or haemopoietic systems, particularly inflammatory or immunodeficiency conditions, such as AIDS.
  • diseases and conditions which include, but are not limited to, diseases of the endocrine and immune or haemopoietic systems, particularly inflammatory or immunodeficiency conditions, such as AIDS.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.immune, hematopoietic, endocrine, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in T-cells and adrenal gland tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune and endocrine systems and cancer.
  • the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological acitivities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g.
  • hematopoiesis e.g. for treating anaemia or as adjunct to chemotherapy
  • stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:98 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 890 of SEQ ID NO:98, b is an integer of 15 to 904, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: SLLMYFVFKIFFQSLCVLGYCILPLTVA (SEQ ID NO:435). Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in dendritic cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.immune. cancerous and wounded fissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:248 as residues: Thr-43 to Thr-48.
  • tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune system disorders.
  • polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases Some of these sequences are related to SEQ ID NO 99 and may have been publicly available prior to conception of the present invention Preferably, such related polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any mteger between 1 to 562 of SEQ ID
  • polypeptides of the invention comprise the following amino acid sequence
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, digestive and gastrointestinal conditions, particularly ulcers and cancers Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g gastrointestinal, metabolic, mucosal, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, chyme, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:249 as residues: Pro-32 to Gly-38.
  • the tissue distribution in stomach tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of gastrointestinal disorders, or other disorders afflicting mucosal or endothehal tissues.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences, such as EST sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 100 and may have been publicly available prior to conception of the present invention.
  • polynucleotides are specifically excluded from the scope of the present invention.
  • a-b is any integer between 1 to 699 of SEQ ID NO: 100
  • b is an integer of 15 to 713, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 100, and where b is greater than or equal to a + 14.
  • the translation product of this gene was found to have homology to the conserved K07F5.14 protein from Caenorhabditis elegans (See Genbank Accession No gnllPIDIe233697) which may be important in regulation of important cellular functions, including homeostasis and cell division.
  • GAS gamma activating sequence
  • GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.
  • the Jak- STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.
  • polypeptides of the invention comprise the following amino acid sequence: RTCTPWMGFWCLVCSLFAPVPTSRKYLVSKPGCYQRRRV FGVCFTKPL (SEQ ID NO 437), WLLSEKKG (SEQ ID NO 438), and/or GVFYKAAVIG (SEQ ID NO 439) Polynucleotides encoding these polypeptides are also encompassed by the invention
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • tissue or cell types e g immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in bone marrow and T-cells combined with the detected GAS biological activity in U937 cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of immune and hormonal disorders and neoplasms Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types
  • the protein may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus- graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 101 is publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 101 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 635 of SEQ ID NO: 101.
  • b is an integer of 15 to 649, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 101, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: CKTSPLPKEGQSAVSVPVSSHFLAHSAPLSGGHAHVFARDGATGL (SEQ ID NO:440), LGRGSGERKTPVSCFAQISKSRGGRSKSLTHLCTHTHTQVTEL DVRMSHGCLRXQHAGRLAPPPPLRFCL TACWGRRGEAETVWKDPASSQ HPPPSEKPHRQDRHPERWHQPGGPIPGKHMRVSPGQRGRVCQEMGRNRN (SEQ ID NO:441), FCLRDFKIWRGRLEAGRTEGRL AGERFGGEEDPSFLFC SDFKVEGWAFEISHSLVHTHTHTGHGAGRADVTRVPAGTARWEAGSPTPSPV LF DSLLGAAGRG (SEQ ID NO:442), AQISKSRGGRSKSLTHLCTHTQVTEL (SEQ ID NO:443), EKPHRQDRHPERWHQPGGPIPGKHMR (SEQ ID NO:444)
  • polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, reproductive, and neurological conditions Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g developmental, reproductive, ovarian, immune, hematopoeitic, and cancerous and wounded tissues) or bodily fluids (e g lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 251 as residues Pro-34 to Pro-53
  • tissue distribution in spinal cord and fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of neural, hematopoietic, and developmental disorders Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception
  • elevated expression of this gene product in regions of the brain indicates that it
  • stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include, but are not limited to bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 102 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 683 of SEQ ID NO: 102, b is an integer of 15 to 697, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 102, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: DEGVQGERLFRILRINGEKPYNFVDYFHCEY (SEQ ID NO:447), KVVRIDNGILCSHKKTEIMSLQQHGWIWRPYLKQTNTGTENQIPHTL TYKWELNFEYIXTQXRGXXDSEAYLKVEGGRREGIQKLPIRYYVYYLGDKIICT SSSCSMHLLM (SEQ ID NO:448), HKDTCMSMFT AALFTIAKTWN (SEQ ID NO:447), KVVRIDNGILCSHKKTEIMSLQQHGWIWRPYLKQTNTGTENQIPHTL TYKWELNFEYIXTQXRGXXDSEAYLKVEGGRREGIQKLPIRYYVYYLGDKIICT SSSCSMHLLM (SEQ ID NO:448), HKDTCMSMFT AALFTIAKTWN (SEQ ID NO:447), KVVRIDNGILCSHK
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal, urogenital, and nephrotic conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.renal, bladder, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:252 as residues: Arg-52 to Ala-57, Pro-66 to Thr-72.
  • the tissue distribution in bladder tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of gastrointestinal and urinary tract disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences, such as EST sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 103 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention.
  • a-b is any integer between 1 to 1274 of SEQ ID NO: 103
  • b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 103, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal, renal, and urinary tract conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.renal, urogenital.
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in bladder tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of urinary tract and gastrointestinal disorders.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 104 Some of these sequences are related to SEQ ID NO: 104 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1013 of SEQ ID NO: 104, b is an integer of 15 to 1027, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 104, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: LHGEQVPI YIFLLMQPLNFECISFLNCIEQYSVGVI HNSV TIYACDREENCMDIRYL (SEQ ID NO:454), and/or GTSWASRFFTCH (SEQ ID NO:455).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in T-cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory disorders, particularly immunodeficiencies such as AIDS.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another fissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:254 as residues: Lys-28 to Thr-34.
  • tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune system.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity
  • this gene product may have commercial utihty in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 696 of SEQ ID NO: 105, b is an integer of 15 to 710, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 105. and where b is greater than or equal to a + 14.
  • a-b is any integer between 1 to 696 of SEQ ID NO: 105
  • b is an integer of 15 to 710
  • both a and b correspond to the positions of nucleo
  • polypeptides of the invention comprise the following amino acid sequence
  • polynucleotides encoding these polypeptides are also encompassed by the invention This gene is expressed primarily in lymphoma and frontal cortex Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and haemopoietic diseases particularly neurodegenerative conditions such as Alzheimers and Parkinsons Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ss
  • tissue distribution in frontal cortex and lymphoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the neural and haemopoietic systems Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuiopathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception
  • elevated expression of this gene product in regions of the brain indicates that it
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 106 is publicly available and accessible through sequence databases
  • b is an integer of 15 to 530, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 106, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in the spleen of a patient with metastatic melanoma
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune or hematopoietic disorders, particularly metastatic melanoma and other cancers, as well as immune disorders and conditions such as anemias, AIDS. arthritis and asthma.
  • diseases and conditions which include, but are not limited to. immune or hematopoietic disorders, particularly metastatic melanoma and other cancers, as well as immune disorders and conditions such as anemias, AIDS. arthritis and asthma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g., immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:256 as residues: Pro-26 to Asn-34.
  • tissue distribution in spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of metastatic melanomas and other cancers, as well as other immune disorders and conditions including leukemias, lymphomas, AIDS, arthritis, asthma and microbial infection. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, or thrombocytopenia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 107 Some of these sequences are related to SEQ ID NO: 107 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 378 of SEQ ID NO: 107, b is an integer of 15 to 392, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 107, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: GTVTQKRK CVFGKYLLSTCSLMFSSMHGACSWKA KQTSSSAGFLCLHVLCPALQLTREKYKTWPWPSFI (SEQ ID NO:458), and/or MKEGQGHVLYF SRVNCKAGHXTCRQRKPADELVCFAFQEQAPCILLNI
  • RLQVLNKYLPNTHFLFCVTVP SEQ ID NO:459.
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8. This gene is expressed primarily in pineal gland and synovial sarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine or skeletal disorders, including cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endocrine, pineal, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the endocrine system.
  • polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g.
  • hypothallamus hypothallamus
  • testes hypothallamus
  • the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie.
  • connective tissues e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation
  • various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and
  • Protein, as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 108 Some of these sequences are related to SEQ ID NO: 108 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 977 of SEQ ID NO: 108, b is an integer of 15 to 991 , where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 108, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence:
  • TMTGIDSSPEELLRQVGCKQQQGKGVEHVEGSSAEAGEAARGGGAK GGGG AAGKGTSKVGTLRRTRGST SEQ ID NO:460.
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in breast and fetal spleen.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the reproductive system and developing organs, particularly congenital defects afflicting the immune or hematopoietic system, such as immunodeficiencies.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g reproductive, developing, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 258 as residues Gly-23 to Asn-30, Ser-37 to Asn-43
  • the tissue distribution in fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases involving developmental tissues and reproductive organs
  • the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements It may also have a very wide range of biological acitivities Typical of these are cytokine.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 109 may have been publicly available p ⁇ oi to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 898 of SEQ ID NO 109, b is an integer of 15 to 912, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 109, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence AQREAGSRPRRRKSLKAVAMLXVEMGGGCRGSMGPGPGYS AGSRVCRGSSL PQVAPFNPSRAHLLPPPVG GGLNSVWLSGVQLSTPPYADWEGVGQSPQ PRGPWMGSSSLGTVGPGCVLSGCPTVKANGGSPCSEMLGER RLLEPSVG PVSGCPERREGGHGARGAAGVVVKGHASVQLNFLSLI (SEQ ID NO 461).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases involving immune, endothehal, and haemopoietic tissues or cells, particularly cancers, inflammatory or immunodeficiency conditions
  • diseases and conditions which include, but are not limited to, diseases involving immune, endothehal, and haemopoietic tissues or cells, particularly cancers, inflammatory or immunodeficiency conditions
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g endothehal, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum
  • tissue distribution in immune and hematopoietic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the immune and haemopoietic systems, including cancer. More specifically, this gene product may be involved in the regulatic j, of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions.
  • immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.
  • immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia,
  • this gene product may have commercial utihty in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 110 amino acid sequences
  • amino acid sequences are related to SEQ ID NO: 110 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 861 of SEQ ID NO: 1 10, b is an integer of 15 to 875, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 1 10, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: GKPLSAIFPICH MMFLPGKFNLGISHRCCRMT SPWDK RQQLRQECKSDPHVQNPRIHFPESKNSFPSAYIFVSEGNGVSPSK WHCIY SGTSLSH (SEQ ID NO:466), and/or GERGRYQSKYSATWMVTPHYLQTQRC KLREMNSWIQGNEFLDSEHEGQIYIPVSIVDAYPKD (SEQ ID NO:467). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. kidney, urogenital, hepatic, and endocrine disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:260 as residues: Glu-38 to Lys-43.
  • kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome.
  • kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's
  • liver disorders and cancers e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 111 Some of these sequences are related to SEQ ID NO: 111 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 445 of SEQ ID NO: 1 11, b is an integer of 15 to 459, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 1 11, and where b is greater than or equal to a + 14.
  • kidney cortex This gene is expressed primarily in kidney cortex and fetal tissue.
  • utihty The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 112 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 112 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 595 of SEQ ID NO: 1 12, b is an integer of 15 to 609, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 112, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and neurological conditions, particularly prohferative disorders, such as ovarian cysts or cancer, in addition to neurodegenerative conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in ovarian tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of reproductive disorders, such as infertility.
  • polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyehnating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.
  • this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1390 of SEQ ID NO: 113, b is an integer of 15 to 1404, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:l 13, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence: ISIRGRIL
  • HSKQNICREVNILKMFLHEIKKTVTDNISTQRRFTYNHQPGS VSIFSVTDILDFEVPFGL SEQ ID NO:470.
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or integumentary system disorders, and cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.integumentary, immune, hematopoieitc, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of cancers and immune system disorders. Alix.
  • melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port- wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.
  • congenital disorders i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port- wine syndrome
  • integumentary tumors i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and
  • autoimmune disorders i.e. lupus eryfhematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus
  • keloids striae. erythema, petechiae, purpura, and xanthelasma.
  • disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e.
  • the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chrondomalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 114 Some of these sequences are related to SEQ ID NO: 114 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 839 of SEQ ID NO: 114, b is an integer of 15 to 853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 114, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or integumentary disorders, particularly lymphatic and soft tissue cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.immune, hematopoietic, integumentary, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in B-cell lymphoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc.
  • this gene product may have commercial utihty in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • the protein product of this gene may also be useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.
  • autoimmune disorders i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus
  • keloids i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus
  • striae erythema, petechiae, purpura, and xanthelasma.
  • such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e.
  • the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chrondomalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 115 Some of these sequences are related to SEQ ID NO: 115 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 831 of SEQ ID NO: 1 15, b is an integer of 15 to 845, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 115, and where b is greater than or equal to a + 14.
  • polypeptides of the invention comprise the following amino acid sequence:
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or developmental disorders, including immunodeficiencies and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g.immune, hematopoietic, developmental, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID
  • tissue distribution in B-cells and fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of immune and developmental disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages.
  • the uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.
  • the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders.
  • developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 116 Some of these sequences are related to SEQ ID NO: 116 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 746 of SEQ ID NO: 116, b is an integer of 15 to 760, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 1 16, and where b is greater than or equal to a + 14.
  • An additional embodiment is the polynucleotides encoding these polypeptides.
  • This gene is expressed primarily in keratinocytes and tissues undergoing wound healing, and to a lesser extent, in osteoblasts and smooth muscle.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders; fibrosis; scarring; osteoporosis; osteopetrosis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • tissue distribution in keratinocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of skin disorders. Elevated expression of this protein in skin and keratinocytes suggest that it may be involved in keratinocyte proliferation, survival, and/or differentiation. Thus, it may play a role in such processes as fibrosis and wound healing. Similarly, expression of this protein in osteoblasts indicates that it may also play a role in osteoblast survival, proliferation, and/or differentiation, and that it may be useful in the treatment of such disorders as osteoporosis or osteopetrosis.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 117 Some of these sequences are related to SEQ ID NO: 117 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 974 of SEQ ID NO: 1 17, b is an integer of 15 to 988, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 117, and where b is greater than or equal to a + 14.
  • the translation sequence of this gene shares homology with a mouse camodulin binding protein.
  • the calcium-binding regulatory protein calmodulin is an essential subunit of the erythrocyte and other plasma membrane calcium ATPases. A rise in cytosolic calcium induces the binding of calcium ions to calmodulin, which triggers an allosteric activation of the calcium ATPase, and subsequently an export of calcium ions from the cell is accelerated.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental defects, calcium-transport defects, in addition to immune or hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. developing tissues, immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID
  • tissue distribution in teratocarcinoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental defects as well as for organ regeneration.
  • expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other prohferative disorders.
  • developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • the homology of the translation product of this gene to a mouse calmodulin binding protein indicates that the translation product of this gene may be useful for disorders involving calcium transport across the plasma membrane, for example. It has further been suggested this type of disorder may be responsible for disorders such as hypertension.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 118 Some of these sequences are related to SEQ ID NO: 118 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO 118, b is an integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 118, and where b is greater than or equal to a + 14
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g ovaries, breast, cancerous and wounded tissues) or bodily fluids (e g lymph, serum, breast milk, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 268 as residues Arg-24 to Arg-29
  • tissue distribution in ovarian tumor tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer, particularly ovarian and breast cancers.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 119 Some of these sequences are related to SEQ ID NO: 119 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1434 of SEQ ID NO: 119, b is an integer of 15 to 1448, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 119, and where b is greater than or equal to a + 14.
  • the translation product of this gene shares sequence homology with bovine acrosin inhibitors Ila and lib which is thought to be important as protease inhibitors. This gene is expressed primarily in keratinocytes.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary disorders, such as psoriasis, and wound healing abberations.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.integumentary, and cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:269 as residues: Tyr-39 to Lys-58.
  • tissue distribution in keratinocytes combined with the homology to the bovine acrosin inhibitors Ila and lib indicates that polynucleotides and polypeptides corresponding to this gene are useful for the acceleration of wound healing.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 120 Some of these sequences are related to SEQ ID NO: 120 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO: 120, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 120, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; lymphomas.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. immune, hematopoietic, and cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:270 as residues: Glu-28 to His-34.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders.
  • This gene product is primarily expressed in hematopoietic cells and fissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoieitic lineages. This is particularly supported by the expression of this gene product in fetal liver and bone marrow, the two primary sites of definitive hematopoiesis.
  • this gene product in T cells and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance. Furthermore, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 121 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 121 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1160 of SEQ ID NO: 121, b is an integer of 15 to 1174, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 121, and where b is greater than or equal to a + 14.
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.
  • This gene is expressed primarily in fetal liver, spleen, and to a lesser extent in melanocyte.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. developmental, integumentary, or hematopoeitic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • tissue distribution in fetal liver and spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of developmental hematopoeitic disorders. Additionally, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders.
  • This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoieitic lineages. This is particularly supported by the expression of this gene product in fetal liver, which is a primary sites of definitive hematopoiesis, and strongly suggesting a role for this protein in immune function and immune surveillance
  • polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 122 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention.
  • a-b a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1032 of SEQ ID NO.122, b is an integer of 15 to 1046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 122, and where b is greater than or equal to a + 14
  • the gamma activating sequence is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.
  • the Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, B cell lymphoma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:272 as residues: Gln-23 to Asn-31, Tyr-42 to Ser-58.
  • tissue distribution in B-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of lymphomas, particularly B cell lymphomas.
  • expression of this gene product in B-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).
  • the gene Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.
  • Protein as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues. Additionally, the biological activity data supports the notion that the translational product of this gene activates specific immune cells, and therefore may play a role in the initiation of immune system activity.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 123 Some of these sequences are related to SEQ ID NO: 123 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1146 of SEQ ID NO: 123, b is an integer of 15 to 1160, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 123, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of certain immune disorders, especially those involving neutrophils.
  • Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 124 Some of these sequences are related to SEQ ID NO: 124 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 879 of SEQ ID NO: 124, b is an integer of 15 to 893, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 124, and where b is greater than or equal to a + 14.
  • this gene comprises polpeptides of the following amino acid sequence: DIMPASVLFLICEGVLYGVQG (SEQ ID NO:476).
  • An additional embodiment is the polynucleotides encoding these polypeptides.
  • This gene is expressed primarily in placenta. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, placental insufficiency; developmental abnormalities; aberrant angiogenesis; abnormal development and/or maintenance of the placenta.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e g developing, placental, cancerous and wounded tissues
  • bodily fluids e g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta
  • this gene product may play a role in the proper establishment and maintenance of placental function
  • this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus
  • Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothehal cells or within the circulation In such instances, it may play more generalized roles in vascular function, such as in angiogenesis It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 125 is related to SEQ ID NO 125 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 1035 of SEQ ID NO 125
  • b is an integer of 15 to 1049
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 125
  • b is greater than or equal to a + 14
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary, immune, or skeletal disorders, particularly wound healing and rheumatoid conditions.
  • diseases and conditions which include, but are not limited to, integumentary, immune, or skeletal disorders, particularly wound healing and rheumatoid conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. skin, connective tissues, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID
  • tissue distribution in keratinocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of integumentary disorders, particularly with regard to wound healing. Furthermore, the tissue distribution also indicates that the translation product of this gene is useful for the treatment and/or detection of disorders of the connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie.
  • connective tissues e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation
  • various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism,
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 126 Some of these sequences are related to SEQ ID NO: 126 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1612 of SEQ ID NO: 126, b is an integer of 15 to 1626, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 126, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatic, neural, or reproductive disorders, particularly metastatic liver cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • bodily fluids e.g. lymph, serum, seminal fluid, amniotic fluid, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in hepatic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some types of cancer including hepatoma, testes tumor and related metastases. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • liver disorders and cancers e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 127 Some of these sequences are related to SEQ ID NO: 127 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1163 of SEQ ID NO: 127, b is an integer of 15 to 1177, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 127, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in CD34 positive cells, and to a lesser extent, in pancreatic tumor and spleen.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, endocrine, or immune disorders, particularly pancreatic cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, liver, spleen, cancerous and wounded tissues) or bodily fluids (e.g.
  • tissue distribution in pancreatic and CD34 positive cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some types of cancer, especially those involving CD34 cells and pancreatic cancer.
  • expression of this gene product in both CD34 positive cells and spleen indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).
  • the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, z, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 128 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 128 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1262 of SEQ ID NO: 128, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 128, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in osteoclastoma, fetal liver/spleen, and to a lesser extent, in primary dendritic cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, osteoclastoma; hematopoietic disorders; lymphomas; impaired immunity; immune disorders; inflammation, in addition to integumentary disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • bodily fluids e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:278 as residues: Thr-23 to Pro-29, Thr-68 to Pro-76.
  • the tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of bone and hematopoietic disorders. Elevated levels of expression of this gene product in osteoclastoma indicates that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis.
  • this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the numbers of stem cells and committed progenitors.
  • Expression of this gene product in primary dendritic cells also indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance.
  • polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 129 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1320 of SEQ ID NO: 129. b is an integer of 15 to 1334, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 129, and where b is greater than or equal to a + 14.
  • EGRl Early growth response 1
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, soft tissue cancers, such as hemangiopericytoma, in addition to other prohferative conditions.
  • diseases and conditions which include, but are not limited to, soft tissue cancers, such as hemangiopericytoma, in addition to other prohferative conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s).
  • tissue or cell types e g. circulatory system, and cancerous and wounded tissues
  • bodily fluids e.g lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hemangiopericytoma.
  • the biological activity data demonstrates that the translation product of this gene activates fibroblast cells Fibroblast cells have the abihy to undergo vascula ⁇ zation, and thus the translation product of this gene may be involved in disorders of the vascular tissue, such as hemangiopericytoma.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 130 Some of these sequences are related to SEQ ID NO: 130 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 518 of SEQ ID NO: 130, b is an integer of 15 to 532, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 130, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal or urogenital disorders, particularly nephritis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain fissues or cell types (e.g. kidney, cancerous and wounded fissues) or bodily fluids
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • kidney cortex indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the kidney, including nephritis.
  • tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 131 Some of these sequences are related to SEQ ID NO: 131 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • a-b is any integer between 1 to 671 of SEQ ID NO: 131, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 131, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in spleen from chronic lymphocytic leukemia.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disordes, such as chronic lymphocytic leukemia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. spleen, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of chronic lymphocytic leukemia. Furthermore, the expression observed predominantly in spleen cells also indicates that the polynucleotides or polypeptides are important in treating and/or detecting hematopoietic disorders, such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease.
  • hematopoietic disorders such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease.
  • polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation.
  • hematopoietic progenitor cells e.g., bone marrow cells
  • the polypeptides or polynucleotides are also useful to increase the proliferation of peripheral blood leukocytes, which can be used in the combat of a range of hematopoietic disorders, including immmunodeficiency diseases, leukemia, and septicemia.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 132 may have been publicly available prior to conception of the present invention.
  • polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 715 of SEQ ID NO: 132, b is an integer of 15 to 729, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 132, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in neutrophils, dendritic cells, and CD34 positive cells (Cord Blood).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune, hematopoietic, or developmental disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of some types of immune disorders, especially those involving neutrophils. More generally, as evidenced by expression in CD34 positive cells, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the numbers of stem cells and committed progenitors. Expression of this gene product in primary dendritic cells also indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance.
  • polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 133 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention To list every related sequence is cumbersome Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1065 of SEQ ID NO 133, b is an integer of 15 to 1079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 133, and where b is greater than or equal to a + 14
  • This gene is expressed primarily in adult lung
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g respiratory, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, l e , the expression level in healthy tissue or bodily fluid from an individual not having the disorder
  • tissue distribution in lung tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of respiratory disorders, such as asthma, emphysema, and ARDS Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • Many polynucleotides and polypeptides corresponding to this gene are useful for treatment
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19. This gene is expressed primarily in T-cell lymphoma and fetal liver/spleen.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, developmental, or hematopoietic disorders, particularly lymphomas.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g.
  • epitopes include those comprising a sequence shown in SEQ ID NO: 1
  • tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of T-cell lymphoma.
  • expression of this gene product in fetal liver/spleen indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.
  • This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO 135 is related to SEQ ID NO 135 and may have been publicly available prior to conception of the present invention
  • polynucleotides are specifically excluded from the scope of the present invention
  • a-b is any integer between 1 to 603 of SEQ ID NO 135
  • b is an integer of 15 to 617
  • both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 135, and where b is greater than or equal to a + 14
  • the translation product of this gene shares sequence homology with C9, a gene of unknown function
  • the gene encoding the disclosed cDNA is thought to reside on chromosome 3 Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3
  • One embodiment of this gene comprises the polypeptides of the following amino acid sequence
  • This gene is expressed primarily in placenta, and to a lesser extent, in apoptotic T-cells, as well as in smooth muscle, testes, and microvascular endothehal cells
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or reproductive disorders
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, muscular, vascular, and cancerous and wounded tissues) or bodily fluids (e.g.
  • tissue distribution in T-cells combined with the homology to the C9 protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some immune disorders, especially those involving T-cells.
  • this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses), or male infertility. Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 136 Some of these sequences are related to SEQ ID NO: 136 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1297 of SEQ ID NO: 136, b is an integer of 15 to 1311, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 136, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune or hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some immune disorders, especially those involving neutrophils. Furthermore, as evidenced by expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utihty as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 137 Some of these sequences are related to SEQ ID NO: 137 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1081 of SEQ ID NO: 137, b is an integer of 15 to 1095, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 137, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune or hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:287 as residues: Lys-36 to Asp-42.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some immune disorders, especially those involving neutrophils. Furthermore, as evidenced by the expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 138 Some of these sequences are related to SEQ ID NO: 138 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 678 of SEQ ID NO: 138, b is an integer of 15 to 692, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 138, and where b is greater than or equal to a + 14.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. immune or hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. immune, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:288 as residues: Pro-32 to Gln-38, Gly-51 to Asp-57.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of certain immune disorders, especially those involving neutrophils. Furthermore, as evidenced by expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in nuetrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 139 Some of these sequences are related to SEQ ID NO: 139 and may have been publicly available prior to conception of the present invention.
  • such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 734 of SEQ ID NO: 139, b is an integer of 15 to 748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 139, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, and cancerous and wounded fissues) or bodily fluids (e.g.
  • lymph, serum, plasma, urine, synovial fluid and spinal fluid or another fissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO:289 as residues: Gly-22 to Ser-28.
  • tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of certain immune disorders involving neutrophils. Furthermore, as evidenced by expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 140 Some of these sequences are related to SEQ ID NO: 140 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1118 of SEQ ID NO: 140, b is an integer of 15 to 1132, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 140, and where b is greater than or equal to a + 14.
  • This gene is expressed primarily in corpus callosum.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to. neural disorders, particularly diseases of the brain, such as neurodegenerative disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. brain, and cancerous and wounded fissues) or bodily fluids (e.g. lymph, serum, plasma, urine.
  • synovial fluid and spinal fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of brian disorders and diseases, including paranoia, schizophrenia, depression, mania, and Alzheimer's disease.
  • elevated expression of this gene product within the corpus callosum of the brain indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • Many polynucleotide sequences such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 141 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO: 141, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 141, and where b is greater than or equal to a + 14.
  • the translation product of this gene shares sequence homology with the putative transposase of the Tigger-1 transposon.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular disorders, particularly muscular atrophy.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in endometrial tissue combine with the homology to a transposase indicates that polynucleotides and polypeptides corresponding to this gene are useful for DNA repair in atrophying tissue, particularly of the endometrium.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO: 142 amino acid sequences
  • amino acid sequences are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 142 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1070 of SEQ ID NO 142, b is an integer of 15 to 1084, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO 142, and where b is greater than or equal to a + 14
  • polypeptides of the invention comprise the following amino acid sequence ARAFQHLMVADHSHFHRTLIKQPSMIPNATFYHIF (SEQ ID NO 478) Polynucleotides encoding these polypeptides aie also encompassed by the invention
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the t ⁇ ssue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, soft tissue tumors, particularly hemangiopericytoma, or other prohferative disorders Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the t ⁇ ssue(s) or cell type(s)
  • expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e g immune, and cancerous and wounded tissues) or bodily fluids (e g lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, I e ,
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO 292 as residues Ser-39 to Ser-44
  • the tissue distribution in hemangiopericytoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of various soft-tissue tumors, in addition to other prohferative disorders which may afflict other tissues or cell types Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues
  • polynucleotide sequences such as EST sequences
  • sequence databases Some of these sequences are related to SEQ ID NO: 143 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1036 of SEQ ID NO: 143, b is an integer of 15 to 1050, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 143, and where b is greater than or equal to a + 14.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or immune disorders,particularly Schizophrenia or neurodegenerative conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cell types e.g. neural, immune, hematopoietic, spleen, cancerous and wounded tissues
  • bodily fluids e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in hypothalamus indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of
  • polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms. hemorrhages, schizophrenia, mania.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)

Abstract

L'invention concerne de nouvelles protéines humaines sécrétées, ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. Elle concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison servant à produire des protéines humaines sécrétées. Elle concerne, de plus, des procédés diagnostiques et thérapeutiques utiles pour diagnostiquer et traiter des maladies relatives à ces nouvelles protéines humains sécrétées.
EP98956146A 1997-10-24 1998-10-23 148 proteines humaines secretees Withdrawn EP1042674A4 (fr)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US6311097P 1997-10-24 1997-10-24
US6309897P 1997-10-24 1997-10-24
US6338797P 1997-10-24 1997-10-24
US6308997P 1997-10-24 1997-10-24
US6310997P 1997-10-24 1997-10-24
US6311197P 1997-10-24 1997-10-24
US6309197P 1997-10-24 1997-10-24
US6309097P 1997-10-24 1997-10-24
US6338697P 1997-10-24 1997-10-24
US6309297P 1997-10-24 1997-10-24
US6314897P 1997-10-24 1997-10-24
US6278497P 1997-10-24 1997-10-24
US6308897P 1997-10-24 1997-10-24
US6309797P 1997-10-24 1997-10-24
US6310197P 1997-10-24 1997-10-24
US6309997P 1997-10-24 1997-10-24
US6310097P 1997-10-24 1997-10-24
US63148P 1997-10-24
US63110P 1997-10-24
US63387P 1997-10-24
US63386P 1997-10-24
US63091P 1997-10-24
US63109P 1997-10-24
US63090P 1997-10-24
US63089P 1997-10-24
US63099P 1997-10-24
US63101P 1997-10-24
US62784P 1997-10-24
US63088P 1997-10-24
US63100P 1997-10-24
US63111P 1997-10-24
US63092P 1997-10-24
US63097P 1997-10-24
US63098P 1997-10-24
PCT/US1998/022376 WO1999022243A1 (fr) 1997-10-24 1998-10-23 148 proteines humaines secretees

Publications (2)

Publication Number Publication Date
EP1042674A1 true EP1042674A1 (fr) 2000-10-11
EP1042674A4 EP1042674A4 (fr) 2005-03-23

Family

ID=27586006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98956146A Withdrawn EP1042674A4 (fr) 1997-10-24 1998-10-23 148 proteines humaines secretees

Country Status (5)

Country Link
EP (1) EP1042674A4 (fr)
JP (1) JP2003521865A (fr)
AU (1) AU1273499A (fr)
CA (1) CA2307320A1 (fr)
WO (1) WO1999022243A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022638A1 (fr) * 2000-09-12 2002-03-21 Human Genome Sciences, Inc. Proteines secretees humaines 22
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002537805A (ja) * 1999-03-05 2002-11-12 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト分泌タンパク質
US6331413B1 (en) 1999-03-17 2001-12-18 Zymogenetics, Inc. Secreted salivary ZSIG63 Polypeptide
WO2000071581A1 (fr) * 1999-05-20 2000-11-30 Takeda Chemical Industries, Ltd. Nouveau polypeptide
FR2796652B1 (fr) * 1999-07-20 2003-03-21 Inst Nat Sante Rech Med Acides nucleiques codant pour des peptides possedant l'activite biologique de la sorbine
CA2388008A1 (fr) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 29 proteines humaines secretees
AU1922301A (en) * 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
EP1280915A1 (fr) * 2000-04-13 2003-02-05 Millennium Pharmaceuticals, Inc. 23155, nouvelle proteine humaine 5-alpha reductases et ses utilisations
AU2003294236A1 (en) * 2002-10-25 2004-05-25 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
TW201100090A (en) * 2009-04-01 2011-01-01 Oncotherapy Science Inc C6orf167 peptides and vaccines containing the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020398A1 (fr) * 1994-01-27 1995-08-03 Human Genome Sciences, Inc. Hormone de croissance humaine
WO1996017931A1 (fr) * 1994-12-09 1996-06-13 Human Genome Sciences, Inc. Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide
WO1996039522A1 (fr) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Chemokine humaine beta-11 et chemokine humaine alpha-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020398A1 (fr) * 1994-01-27 1995-08-03 Human Genome Sciences, Inc. Hormone de croissance humaine
WO1996017931A1 (fr) * 1994-12-09 1996-06-13 Human Genome Sciences, Inc. Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide
WO1996039522A1 (fr) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Chemokine humaine beta-11 et chemokine humaine alpha-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COLEMAN T A ET AL: "Production and purification of novel secreted human proteins" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 190, no. 1, 29 April 1997 (1997-04-29), pages 163-171, XP004064398 ISSN: 0378-1119 *
DATABASE EM_HUM [Online] EMBL; 25 July 1997 (1997-07-25), MUZNY ET AL.: "Human Xp22 BAC CT-285I15 .........." XP002302095 retrieved from EBI accession no. HSAC2366 Database accession no. AC002366 *
MARY P: "Le boom des chimiokines" BIOFUTUR. LE MENSUEL EUROPEEN DE BIOTECHNOLOGY, EDITIONS SCIENTIFIQUES ELSEVIER, PARIS, FR, vol. 1997, no. 165, March 1997 (1997-03), pages 32-37, XP004279638 ISSN: 0294-3506 *
See also references of WO9922243A1 *

Also Published As

Publication number Publication date
AU1273499A (en) 1999-05-17
JP2003521865A (ja) 2003-07-22
CA2307320A1 (fr) 1999-05-06
EP1042674A4 (fr) 2005-03-23
WO1999022243A1 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
US7105644B2 (en) Secreted protein HHTLF25 antibodies
US6420526B1 (en) 186 human secreted proteins
US20050089911A1 (en) 87 human secreted proteins
US20060147982A1 (en) 32 human secreted proteins
US7482442B2 (en) HEMCM42 nucleic acids
WO1999031117A1 (fr) 110 proteines secretees humaines
WO1999058660A1 (fr) 97 proteines humaines secretees
US6525174B1 (en) Precerebellin-like protein
WO1999011293A1 (fr) 50 proteines secretees d'origine humaine
WO1999035158A1 (fr) 36 proteines humaines secretees
US6878687B1 (en) Protein HMAAD57
US7053190B2 (en) Secreted protein HRGDF73
WO1999024836A1 (fr) 125 proteines secretees humaines
WO1999003990A1 (fr) Serie de 64 proteines humaines secretees
WO1999019339A1 (fr) 53 proteines secretees humaines
WO1999022243A1 (fr) 148 proteines humaines secretees
WO1999006423A1 (fr) 83 proteines humaines secretees
WO1999010363A1 (fr) 29 proteines humaines secretees
EP1019506A1 (fr) 101 proteines humaines secretees
US20050214844A1 (en) 86 human secreted proteins
US20070238664A1 (en) 70 Human Secreted Proteins
EP1439189A2 (fr) 86 protéines humainess sécrétées
EP1464653A1 (fr) Protéine humaine sécrétée
EP1445316A1 (fr) Nouvelle protéine secretée
EP1346999A2 (fr) Protéine humaine secrétée

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20050202

17Q First examination report despatched

Effective date: 20050628

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CARTER, KENNETH C.

Inventor name: ENDRESS, GREGORY A.

Inventor name: JANAT, FOUAD

Inventor name: DUAN, D. ROXANNE

Inventor name: FLORENCE, CHARLES

Inventor name: FLORENCE, KIMBERLY A.

Inventor name: GREENE, JOHN M.

Inventor name: YOUNG, PAUL

Inventor name: EBNER, REINHARD

Inventor name: SHI, YANGGU

Inventor name: BREWER, LAURIE A.

Inventor name: OLSEN, HENRIK S.

Inventor name: LAFLEUR, DAVID W.

Inventor name: KAYW, HLA

Inventor name: MOORE, PAUL A.

Inventor name: SOPPET, DANIEL R.

Inventor name: WEI, YING-FEI

Inventor name: NI, JIAN

Inventor name: RUBEN, STEVEN M.

Inventor name: ROSEN, CRAIG A.

Inventor name: FENG, PING

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051109